



Stem Cell Therapy in Limb Ischemia: State-of-Art, Perspective, and Possible Impacts of Endometrial-Derived Stem Cells

Saeed Khodayari^{1,2,3†}, Hamid Khodayari^{2,3,4†}, Somayeh Ebrahimi-Barough¹, Mehdi Khanmohammadi⁵, Md Shahidul Islam¹, Miko Vesovic⁶, Arash Goodarzi¹, Habibollah Mahmoodzadeh², Karim Nayernia³, Nasser Aghdami^{4,7*} and Jafar Ai^{1*}

OPEN ACCESS

Edited by:

Sudjit Luanpitpong,
Mahidol University, Thailand

Reviewed by:

Zhihui Dong,
Fudan University, China
Regina Coeli dos Santos Goldenberg,
Federal University of Rio de Janeiro,
Brazil

*Correspondence:

Jafar Ai
jafar_ai@tums.ac.ir
Nasser Aghdami
nasser.aghdami@royaninstitute.org

[†]These authors share senior
authorship

Specialty section:

This article was submitted to
Stem Cell Research,
a section of the journal
Frontiers in Cell and Developmental
Biology

Received: 13 December 2021

Accepted: 11 April 2022

Published: 23 May 2022

Citation:

Khodayari S, Khodayari H,
Ebrahimi-Barough S,
Khanmohammadi M, Islam MS,
Vesovic M, Goodarzi A,
Mahmoodzadeh H, Nayernia K,
Aghdami N and Ai J (2022) Stem Cell
Therapy in Limb Ischemia: State-of-
Art, Perspective, and Possible Impacts
of Endometrial-Derived Stem Cells.
Front. Cell Dev. Biol. 10:834754.
doi: 10.3389/fcell.2022.834754

¹Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Science, Tehran, Iran, ²Breast Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran, ³International Center for Personalized Medicine (P7MEDICINE), Düsseldorf, Germany, ⁴Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran, ⁵Skull Base Research Center, The Five Senses Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran, ⁶Department of Mathematics, Statistics, and Computer Science, University of Illinois at Chicago, Chicago, IL, United States, ⁷Department of Infectious Diseases and Tropical Medicines, Tehran University of Medical Sciences, Tehran, Iran

As an evidence-based performance, the rising incidence of various ischemic disorders has been observed across many nations. As a result, there is a growing need for the development of more effective regenerative approaches that could serve as main therapeutic strategies for the treatment of these diseases. From a cellular perspective, promoted complex inflammatory mechanisms, after inhibition of organ blood flow, can lead to cell death in all tissue types. In this case, using the stem cell technology provides a safe and regenerative approach for ischemic tissue revascularization and functional cell formation. Limb ischemia (LI) is one of the most frequent ischemic disease types and has been shown to have a promising regenerative response through stem cell therapy based on several clinical trials. Bone marrow-derived mononuclear cells (BM-MNCs), peripheral blood CD34-positive mononuclear cells (CD34⁺ PB-MNCs), mesenchymal stem cells (MSCs), and endothelial stem/progenitor cells (ESPCs) are the main, well-examined stem cell types in these studies. Additionally, our investigations reveal that endometrial tissue can be considered a suitable candidate for isolating new safe, effective, and feasible multipotent stem cells for limb regeneration. In addition to other teams' results, our

Abbreviations: ANGPT2, angiopoietin-2; BDNF, brain-derived neurotrophic factor; BM-MNCs, bone marrow mononuclear cells; CCL-2, C-C motif chemokine ligand 2; CCL5, C-C motif chemokine ligand 5; CD34⁺ MNCs, CD34-positive mononuclear cells; C-Kit, tyrosine protein kinase Kit; CXCL1, X-C motif chemokine ligand 1; CXCL5, X-C motif chemokine ligand 5; CXCL8, C-X-C motif chemokine ligand 8; EGF, epidermal growth factor; ESCs, endometrial stem cells; ERC, endometrial regenerative cells; ESPCs, endothelial stem/progenitor cells; GATA2, GATA-binding factor 2; HLA-DR, human leukocyte antigen—DR; ANGPT2, angiopoietin-2; ICAM-1, intercellular adhesion molecule 1; IL-10, interleukin-10; KDR, kinase insert domain receptor; MSCs, mesenchymal stem cells; NMPB-ACPs, non-mobilized peripheral blood angiogenic cell precursors; NO, nitric oxide; NOS, nitric oxide synthase; IL-8, interleukin-8; PDGF, platelet-derived growth factor; PDGFB, platelet-derived growth factor subunit B; PGPC, *Escherichia coli* K-12; PROM1, prominin 1; SDF-1, stromal cell-derived factor 1; SGPC, streptogrisin-C; TGF- β , transforming growth factor- β ; VCAM-1, vascular cell adhesion protein 1; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor. GFAP, glial fibrillary acidic protein; SOX, SRY (sex-determining region Y)-Box 1; FOXO-3, forkhead box O3; TLX, orphan nuclear receptor TLX; IGF-1, insulin-like growth factor-1; GDNF, glial cell-derived neurotrophic factor; NGF, nerve growth factor.

in-depth studies on endometrial-derived stem cells (EnSCs) have shown that these cells have translational potential for limb ischemia treatment. The EnSCs are able to generate diverse types of cells which are essential for limb reconstruction, including endothelial cells, smooth muscle cells, muscle cells, and even peripheral nervous system populations. Hence, the main object of this review is to present stem cell technology and evaluate its method of regeneration in ischemic limb tissue.

Keywords: stem cell therapy, limb ischemia, state-of-art, perspective, molecular mechanism, endometrial-derived stem cells, regeneration

INTRODUCTION

Peripheral arterial disease (PAD) results in a wide range of organ dysfunction and organ failure in humans. It has been reported that over 200 million PAD cases had been diagnosed just in 2017 globally (Fowkes et al., 2017). Meanwhile, limb ischemia (LI) in particular leads to a large number of these types of disorders (Torbjörnsson et al., 2021). Among these, acute limb ischemia (ALI) and critical limb ischemia (CLI) are considered the most common diagnostic cases of LI, which occur when there is a sudden lack of circulation to limbs due to occlusion of a peripheral artery or bypass graft (Shoji et al., 2020; Torbjörnsson et al., 2021). Through limb ischemia, peripheral arterial disorders, atherosclerotic peripheral vascular disease, and embolic occlusion can directly arise by reducing the blood perfusion into the limb tissues (Narula et al., 2018). Pain in the ischemic regions, thickening of the toenails, skin infections, and limb ulcers are considered the main symptoms of LI (Lambert and Belch, 2013). Interventions such as vascular and endovascular surgery are commonly used as standard approaches to help regulate and promote circulation to ischemic limbs (Almasri et al., 2019). Despite prescribed treatments, a significant number of patients with LIs have to undergo a major lower limb amputation (Fowkes et al., 2017); hence, the development of a safe, minimally invasive, and effective strategy for regenerating degenerated tissues is regarded as the primary strategy for the treatment of the LI.

Nowadays, the undeniable advantage of using stem cell technology is widely acknowledged as a reliable, safe, and effective method for generating mature cells (Khodayari et al., 2021a; Khodayari et al., 2021b) and regenerating injured tissues and organs (Emadedin et al., 2012; Rigato et al., 2017; Khodayari et al., 2019; Hashemian et al., 2021). From a developmental and physiological view throughout the animal's lifetime, stem cells play a vital role in the hemostasis, healing, and regeneration of the organs (Ghazizadeh et al., 2018; Khodayari et al., 2019; Beeken et al., 2021). Based on diverse experimental and clinical studies, stem cell-based therapies have been deemed suitable for managing the damaged limb tissues and improving the LI's symptoms (Zafarghandi et al., 2010; Molavi et al., 2016; Gao et al., 2019).

So far, various types of multipotent stem/progenitor cells have been successfully tested as potential candidates for limb regeneration. The therapeutic potential of BM-MNCs, MSCs, CD34⁺ MNCs, ESPCs, EnSCs, and neural stem cells (NSCs) has been tested on LI patients with different criteria (**Supplementary**

Table S1). Our clinical trials have shown promising results in terms of safety, long-term advantages, and feasibility of the BM-MNC and MSC therapies for limb tissue regeneration/reconstruction targets (Zafarghandi et al., 2010; Emadedin et al., 2012; Molavi et al., 2016). Promoting neovascularization, myogenesis, and neurogenesis, as well as secretion of different paracrine/autocrine factors into the injury microenvironment (**Table 1**), would be the main therapeutic benefit for the damaged limbs resulting from these transplanted stem cells. In this case, inducing therapeutic angiogenesis into the ischemic regions is the chief regenerative mechanism that is promoted by the stem cells (Johnson et al., 2019). This therapeutic response is triggered through the stem cell differentiation to endothelial cells and secreting various types of pro-angiogenic factors into the injured tissue microenvironment (Khodayari et al., 2019). Based on experimental observations, the MSCs, EPCs, and EnSCs are the cells that show both the responses after transplantation (Shamosi et al., 2015; Bouland et al., 2021), while the MNCs have no significant differentiation potential, and it seems their efficacy is induced *via* regulating the ischemic tissue environment (Li et al., 2006). These facts raise the possibility that releasing pro-angiogenic factors can be the main factor for inducing therapeutic angiogenesis into the injured limb.

The EnSCs' biology, differentiation, and regeneration potential have been thoroughly studied during our investigative process. In this regard, we could track the neurogenic, angiogenic, and myogenic potential of the mouse and human EnSCs in both *in vitro* and *in vivo* conditions (Ai and Ebrahimi, 2010; Mobarakeh et al., 2012; Tabatabaei et al., 2013; Khademi et al., 2014; Tehrani et al., 2014; Shamosi et al., 2017). In addition to the basic and clinical observations we have summarized in **Table 1**, **Supplementary Table S1**, our studies could reliably conclude that the EnSCs may be a novel and useful source for regenerating various types of ischemic disorders, along with other stem/progenitor cells (Ai and Ebrahimi, 2010).

Although different clinical examinations report the benefits of cell therapy on the ischemic organs, there are multiple challenges and barriers to achieving satisfactory regeneration in practice. In 2019, Khodayari et al. (2019) hypothesized that the creation of a stressful inflammatory microenvironment following the acute phase of myocardial infarction can be a potential inherent factor in blocking the outcome of cell therapy in this ischemic region. We believe creating this type of natural restriction would be a destructive factor for stem cell therapy goals, not only for infarcted myocardium but also for all other types of ischemic

TABLE 1 | Characteristics, biological activity, and main clinical applications of the approved stem/progenitor cell types for treatment of limb ischemia.

Stem cell type	Developmental origin	Sources	Phenotype	Regeneration potential/generated linages	Paracrine/autocrine factors	Other clinical applications	References
BM-MNCs	Non-hematopoietic origins such as ectoderm, mesoderm, and endoderm	Bone marrow	CD34 ⁺ , PROM1 (CD133) ⁺ , KIT (C-Kit) ⁺ , CD14 ⁻ , and CD45 ⁻	Myogenesis, angiogenesis, osteogenesis, as well as hepatogenesis, and neural lineage differentiation	Cytokines and immune suppressors: NOS, IL-8, IL-10, and TGF- β Growth factors: EGF, PDGF, VEGF, and SDF-1 Chemokine/surface markers: CXCL8, CXCL5, CXCL1, and CCL5	Cardiovascular disorders Diabetes and its related complications Brain diseases and spinal cord injuries Bone fracture and disease Skin regeneration Liver disease	Heldman et al. (2014) (Dubsky et al., 2013; Wu et al., 2014) (Sarasúa et al., 2011; Moniche et al., 2015; Liu et al., 2017) Seebach et al. (2016) Zhou et al. (2016) Mohamadnejad et al. (2016)
MSCs	Somatic lateral plate mesoderm	Bone marrow, peripheral blood, umbilical cord blood/tissue, as well as adipose, muscle, skin, and cardiac tissues	CD73 ⁺ , CD90 ⁺ , 105 ⁺ , CD34 ⁻ , CD45 ⁻ , D11b ⁻ , CD14 ⁻ , CD19 ⁻ , CD79a ⁻ , and HLA-DR ⁻	Myogenesis, angiogenesis, osteogenesis, ligament and tendogenesis as well as hepatogenesis, dipogenesis, and neural lineage differentiation	Cytokines/immune suppressors: NO, IL-10, TGF- β , and CCL-2 Growth factors: EGF, PDGF, VEGF, BDNF, IGF-1 and SDF-1 Chemokines/surface markers: galectin, ICAM-1, and VCAM-1	Cardiovascular disorders Diabetes Brain and spinal cord injuries Multiple system atrophy Pulmonary and respiratory diseases Hepatic disorders Bone fracture and disease Kidney disease Autoimmune disease Skin regeneration	Kim et al. (2018) Bhansali et al. (2017) (Xiao et al., 2018; Levy et al., 2019) Singer et al. (2019) Wilson et al. (2015) Shi et al. (2012) Emadedin et al. (2018) (Makhlough et al., 2017; Makhlough et al., 2018) Liang et al. (2018) Kim et al. (2020)
PB-CD34 ⁺ MNCs	Non-hematopoietic origins such as ectoderm, mesoderm, and endoderm	Peripheral blood, umbilical cord blood, and bone marrow	CD34 ⁺ , CD14 ⁻ , and CD45 ⁻	Myogenesis, angiogenesis, osteogenesis, as well as hepatogenesis, and neural lineage differentiation	Cytokines and immune suppressors: SGPC, PGPC, NOS, IL-8, IL-10, and TGF- β Growth factors: EGF, PDGF, VEGF, and SDF-1, and BDNF Chemokine/surface markers: CXCL8, CXCL5, CXCL1, and CCL5	Cardiovascular disorders Hepatic disorders Hematopoietic recovery flowing chemotherapy	Tendera et al. (2009) Park et al. (2013) Cancelas et al. (1998)

(Continued on following page)

TABLE 1 | (Continued) Characteristics, biological activity, and main clinical applications of the approved stem/progenitor cell types for treatment of limb ischemia.

Stem cell type	Developmental origin	Sources	Phenotype	Regeneration potential/generated linages	Paracrine/autocrine factors	Other clinical applications	References
ESPCs/ NMPB- ACPs	Endothelial and hematopoietic cell lineages	Peripheral blood, umbilical cord blood/tissue, hemogenic endothelium, as well as adipose, muscle, skin, and cardiac tissues	CD34 ⁺ , CD133 ⁺ , ANGPT2 ⁺ , CD144 ⁺ , VEGFR ⁺ , GATA2 ⁺ , PDGFB ⁺ , CD31 ⁺ , CD14 ⁻ , and KDR ⁻	Neovascularization and re-endothelialization	Cytokines and immune suppressors: IL-10, eNOS, and TGF- β Growth factors: VEGF-A, VEGF-B, SDF-1, and IGF-1 Chemokine and surface markers: CXCR-4 and VCAM-1	Cardiovascular disorders Osteonecrosis Diabetes and its related complications	(Lee et al., 2015; Zhu et al., 2016) Daltro et al. (2015) Tanaka et al. (2014)
CTX/ NSCs	Ectoderm	Brain and spinal cord SVZ, oncogene immortalized stem cells, neurospheres, and embryonic stem cell (ES)-derived neural cells	CD184 ⁺ , CD24 ⁺ , nestin ⁺ , FGF-R ⁺ , GFAP ⁺ , SOX1/2 ⁺ , FOXO-3 ⁺ , TLX ⁺ , CD271 ⁻ , and CD44 ⁻	Neural lineage differentiation	Growth factors: EGF, b-FGF, IGF-1, VEGF, GDNF, NGF, and BDNF	Brain and spinal cord injuries Brain cancer treatment Peripheral arterial disease	(Kalladka et al., 2016; Curtis et al., 2018) Portnow et al. (2017)
EnSCs/ ERCs	Mesoderm	Endometrium	CD146 ⁺ , PDGF-R β ⁺ , CD29 ⁺ , CD44 ⁺ , CD73 ⁺ , CD90 ⁺ , CD105 ⁺ , SSEA-1 ⁻ , CD34 ⁻ , CD31 ⁻ , and CD45 ⁻	Myogenesis, angiogenesis, osteogenesis, ligament and tendogenesis as well as hepatogenesis, adipogenesis, and neural lineage differentiation	Cytokines/immune suppressors: NO, IL-10, TGF- β , and CCL-2 Growth factors: EGF, PDGF, VEGF, BDNF, IGF-1, and SDF-1 Chemokines/surface markers: galectin, ICAM-1, and VCAM-1	Cardiovascular disorders Peripheral vascular diseases	Bockeria et al. (2013) Zhong et al. (2009)

disorders. It seems that 1) developing modern technologies to reduce the cost of manufacturing stem cells at the highest level, 2) creating next-generation stem cells compatible with the ischemic microenvironment, and 3) presenting new available stem cell sources with greater regenerative potential will be the adequate targets to achieve more efficient tissue regeneration in practice. The scope of this review article is to first describe the molecular mechanisms of pathogenesis of limb ischemia. After summarizing our clinical experiences and the other latest clinical trials on LI stem cell therapy, we will present our group's obtained evidence that could illustrate the EnSCs' therapeutic impacts on limb regeneration. Finally, we will outline the limitations and perspectives of the cell therapy approach for the regeneration of limb ischemia.

LIMB ISCHEMIA PATHOGENESIS: PATHWAYS AND MECHANISMS

Based on recent studies, peripheral arterial disorder is the main factor in the progression of hind limb ischemia (HLI). Chronic and acute arterial occlusions are caused primarily by occlusive

arterial diseases and could block the blood perfusion into the limbs, as well as related tissues and organs (Heo et al., 2017). During the ischemia pathogenesis, decreasing the hypoxic cell's metabolism, increasing the level of intracellular free radicals, and forming a stressful inflammatory network in the ischemic tissue microenvironment can negatively disturb the cellular population's viability and function (Khodayari et al., 2019).

It is reported that oxidative stresses, which interfere by increasing intracellular levels of reactive oxygen and nitrogen species (ROS and RNS), are the primary disruptive factors in the ischemia pathogenesis path (Schröder et al., 2012; Bagheri et al., 2016). Meanwhile, all limb tissue cell types, including endothelial cells, skeletal myocytes, fibroblasts, and peripheral neurons, have been shown to present identical pathogenic responses to intracellular ROS and RNS generation (Steiling et al., 1999; Wang et al., 2015; Cheng et al., 2016). Activation of reactive species can directly cause cell damage through DNA sequence alteration, gene amplification, and expression of some proto-oncogenes and tumor suppressor genes (Bagheri et al., 2016; Qiu et al., 2019). In most cellular populations, mitochondria organelles are the main targets of ROS-mediated signaling in the path of HLI pathogenesis. In more detail, production of ROS




FIGURE 1 | Schematic representation of the main molecular mechanisms involved in limb ischemic pathogenesis. Two types of apoptotic skeletal muscle cells with fragmented nuclei under hypoxic stress and skeletal muscle cells are shown. Following ischemia, endogenous ROS production is induced early after injuries. Cytoplasmic ROS via chains of mPTPs opening of the mitochondrial membrane, releasing of the cyto c into the cells' cytoplasm, and activation and intra-nucleus accumulation of NF-κB through MAPK signaling stimulation, leads to the muscle cells' apoptosis and necrosis. In addition to, stimulation of the TNF-R1/2, IL-1R, and TRAIL-R, as the main death ligands, by activation of the caspase cascades has a dominant role in developing the muscle cell's injuries. **Abbreviations:** Cyt-C, cytochrome-C; ERK, extracellular signal-regulated kinases; Fas, apoptosis antigen 1 (APO-1 or APT); IL-1R, interleukin-1 receptor; IL-1β, interleukin-1β; MAPK, mitogen-activated protein kinase; NFκB, nuclear factor kappa-light-chain enhancer of activated B cells; ROS, reactive oxygen species; TNF-R, tumor necrosis factor receptor; TNF-α, tumor necrosis factor-α; TRAIL, TNF-related apoptosis-inducing ligand; TRAIL-R, TNF-related apoptosis-inducing receptor. Figure created with BioRender.com.

is directly controlled by the ischemic cell's mitochondria electron transport chain (ETC) overactivity (Indo et al., 2007). Moreover, ROS directly switches cytoplasmic Ca²⁺ accumulation. This mechanism leads to interference of the injured cell's mitochondrial permeability transition pore (mPTP) opening and affects the mitochondrial membrane potential (Batandier et al., 2004). This mitochondrial mechanism immediately stimulates apoptosis cell death in the ischemic tissues by releasing cytochrome-c protein into the injured cell's cytoplasm, which, in turn, progresses the caspase cell death cascade (Figure 1). Aside from the cytochrome-c accumulation, some other harmful function cascades are caused by the ROS/mitochondria interaction with the injured cells. The cytoplasmic expression of apoptotic factors like B-cell lymphoma 2 (BCL-2), BCL-2-associated X protein (BAX), BCL-2-associated death promoter (Bad), and glycogen synthase kinase 3β (GSK-3β) are the other main factors involved in this path (Perrelli et al., 2011) (Figure 1).

In contrast with the apoptotic mechanisms, several protective pathways can be initiated by the stressed mitochondria in response to ROS (Stein et al., 2017). The protein kinase C (PKC) signaling pathway is one of the main types of these protective mechanisms, which also plays multiple roles in the development and hemostasis of organs (Stein et al., 2017; Khodayari et al., 2019). In addition to the mitochondrial electron transport chain (ETC), the PKC and nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, other main cell protective factors could be broadly released from different origins, including the xanthine oxidase, cyclooxygenase, and lipoxygenase (Leslie et al., 2004). In this regard, the generated ROS can directly target the PKC release into the injured cell cytoplasm through stimulation of the mitochondrial function. From another path, the activated PKC directly generates ROS production through NADPH phosphorylation (Lee et al., 2004). The activated NADPH improves cells' survival and function inside the stressful

environment through activation of protective signaling pathways, including the apoptosis signal-regulating kinase-1 (ASK1) and AKT pathways (Cosentino-Gomes et al., 2012) (**Figure 1**).

In addition to PKC, the mitogen-activated protein kinases (MAPKs), stress-activated protein kinases (SAPKs), phosphoinositide 3-kinase (PI3K), and ataxia-telangiectasia mutated (ATM) pathways can also serve as cell protective mechanisms which become activated as a result of ROS activity (Cosentino-Gomes et al., 2012). It has been identified that progression of both MAPK and SAPK activation of Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling can protect the injured cells from the disruptive impacts of oxidative stress. In this described cascade, activated PI3K can significantly protect injured cells as well as distant cells by promoting 3 phosphoinositide-dependent protein kinase-1/Akt (PDK1/Akt) signaling (Cosentino-Gomes et al., 2012). The aforementioned pieces of evidence intensively prove this hypothesis, which states that ROS can directly act as a “double-edged sword” in the HLI pathogenesis process (**Figure 1**).

In addition to the described mitochondrial-associated mechanisms, non-mitochondrial ROS-mediated cell death plays a major role in limb tissue oxidative stress. In this process, generation and activation types of well-known inflammatory network elements including tumor necrosis factor- α (TNF- α) and its downstream targets have a central role in evolving the cellular death and limb tissue degeneration (Seekamp et al., 1993). It seems that this referred pro-inflammatory cytokine stimulates the same pathological responses for all organs and tissues, as well as the HLI (Khodayari et al., 2019). It has been shown that in following the limb tissue ischemia, the TNF- α production is directly initiated by overexpression of some adhesion molecules from ischemic tissue's vascular endothelial cells (Simon et al., 2018). According to contemporary observations, TNF- α is the initial and primary pro-inflammatory paracrine factor that directly switches the cytokine changes in the ischemic microenvironment (Heath et al., 2018). TNF- α , through the stimulation of leukocytes, initiates the inflammation process and recruitment of the inflammatory immune cells into the ischemic injured limb tissue. Subsequently, as a result of this mechanism, the expression of other types of pro-inflammatory cytokines, including interleukin-1 β (IL-1 β), interleukin-6 (IL-6), and interleukin-8 (IL-8), occurs in infarcted tissues (Khodayari et al., 2019). It should be noted that this complex and stressful environment is considered the main reason for different inflammatory/degenerative disorders (**Figure 1**).

Furthermore, following the TNF- α associated pathogenicity, stimulation of the TNF- α receptors (TNF-Rs) as one of the main inflammatory cell death ligands can play the pivotal role in tissue degeneration (Sedger and McDermott, 2014). Promoting nuclear factor-kappa B (NF- κ B) cascade, following TNF-R activation, can induce the cellular death process (apoptosis and necroptosis) into the injured cells (Kim et al., 2011). Like TNF- α , IL-1 β -induced NF- κ B activation is another pathogenic factor that occurs after the HLI process (Khodayari et al., 2019). The expressed NF- κ B, through the activation of other pro-apoptotic factors including

the inducible nitric oxide synthase (iNOS), BH3 interacting domain death agonist (Bid), and c-Jun N-terminal kinases/P38 (JNK/P38), can conduct the limb cells toward apoptosis (Cnop et al., 2005). Finally, it should be mentioned that all of the aforementioned adverse mechanisms are just a meager part of the pathogenic and progressive process that is activated in the ischemic limb tissue microenvironment.

STEM CELL THERAPY APPROACHES FOR LIMB ISCHEMIA IN PRACTICE

In the past decade, stem cell-based therapy approaches have become extremely useful facilitators for the regulation of different types of human disorders, including acute and chronic limb ischemia (Zafarghandi et al., 2010; Mardanpour et al., 2019). From a translational and practical view, the performance of some multipotent stem/progenitor cells, including the BM-MNCs, CD34⁺ MNCs, MSCs, and ESPCs, has been approved and deeply studied in different clinical trials (**Supplementary Table S1**). Furthermore, the therapeutic effects of EnSCs and NSCs are investigated in some published and ongoing clinical trials on limb lesions (**Supplementary Table S1**). Generally, the therapeutic benefits from these stem cells can be used in all phases of limb ischemia (Jaluvka et al., 2020). However, types of signs include patient survival rate lower than 6 months, history of malignancy, chronic renal disorders on dialysis therapy, or ALI cases with an advanced inflammatory reaction considers as the contraindication of the LI stem cell therapy (Jaluvka et al., 2020).

In this section, we will briefly review the biological function and regenerative outcomes of the aforementioned stem cells based on the latest clinical observations. Finally, at the end of this section, we will present the EnSCs as an “all-in-one” therapeutic approach for limb regeneration, based on our findings.

Bone Marrow-Derived Mononuclear Cells

Generally, the BM-MNCs, as a heterogeneous cell population, are carefully characterized through the positive expression of CD34, CD45, CD133, and stromal precursor antigen-1 (STRO1) markers from bone marrow aspirated cells (Liang T. W. et al., 2016). It has been reported that the injected BM-MNCs, through the release of various anti-inflammatory cytokines and growth factors (**Table 1**), could regulate the ischemic region's pathogenic mechanisms. In addition, the vasculogenic, myogenic, and neurogenic differentiation potentials of these cells have been clearly recognized by numerous investigations (**Table 1**). According to these complementary features, the BM-MNCs are considered to be a major population in the target regeneration. However, some main drawbacks, such as the high possibility of contamination leading to a long time to culture and mainly decreased cell volume and regenerative capacity due to the increasing age of patients, can affect the use of the BM-MNCs for limb regeneration (Laurence et al., 2015).

So far, different studies have been conducted in order to evaluate the benefits of BM-MNC transplantation as a means

of managing limb ischemic injuries (**Supplementary Table S1**). From 2008 to 2011, we launched two separate clinical trials (phases I/II randomized control trials) for the autologous BM-MNC therapy of patients with CLI (ClinicalTrials.gov identifiers: NCT00677404 and NCT01480414). In those continued clinical observations, we focused on the most pressing questions, including 1) is autologous transplantation of the BM-MNCs safe in patients with CLI, 2) how much simultaneous injection of granulocyte-colony stimulation factor (G-CSF) with the transplantation of BM-MNCs would increase the efficacy of cell therapy in CLI patients, 3) can interval implantation of the BM-MNCs improve the treatment efficacy, and 4) can the BM-MNCs interval injection increase collateral vessel formation in patients with limb ischemia? Following these trials, we stated that the administration of BM-MNCs is a safe and feasible approach for the treatment of patients. Our evaluations additionally showed that the intervention hand was able to improve some patients' clinical indexes, including pain-free walking distance and Wagner stage, besides reduction in ulcer size (Zafarghandi et al., 2010; Molavi et al., 2016).

In a successful study, Tateishi-Yuyama et al. (2002) published an article titled "therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells." Their clinical trial has shown that direct intramuscular injection of CD34⁺ BM-MNCs not only is able to induce an angiogenic response but can also significantly improve the patient's limb function and ankle-brachial pressure index (ABI) 6 months after cell therapy (Pignon et al., 2017). Similar to the aforementioned study, current clinical observations are also displaying an identical therapeutic impact that occurred from the BM-MNCs administration on the limb ischemia cases. Pignon et al. (2017), through intramuscular injection of the CD34⁺ BM-MNCs on patients with CMI, observed a suitable and remarkable therapeutic response within 6 months after cell therapy. Finally, they concluded that "BMSC therapy reduced the risk of major amputations in patients presenting with nonrevascularizable CLI" (Pignon et al., 2017).

Similarly, autologous bone marrow mononuclear cell (ABMNC) therapy is another approach that improves measures of limb perfusion, rest pain, wound healing, and amputation-free survival at 1 year in patients with CLI. As an example, Tateishi-Yuyama et al., in a retrospective study, evaluated the incidence of cardiac, malignant, and other medical events relevant to the safety of cell therapy. They found that none of the patients developed tumorigenesis or clinically significant retinopathy. Mainly, they found that in arms treated with ABMNC, the rates of amputation-free survival, major amputation, and major adverse limb events were significantly higher than in the control group (Tateishi-Yuyama et al., 2002).

Although in recent years, scientists have announced some remarkable therapeutic methods for regenerating the limb ischemia cases based on the administration of BM-MNCs, various gaps and problems have already existed in this path (Liang T. W. et al., 2016). It seems that there was a correlation between the reputation and numbers of the implanted BM-MNCs and regeneration outputs in the IL cases. Hence, our observation

in 2016 has been compared with the therapeutic output that resulted from a single and repeated (4 step) intramuscular injection of $1-2 \times 10^5$ BMDC/kg on CLI patients (**Figure 2**). The results of this study revealed a significant improvement in the repeated treated cases "ABI, visual analog scale, pain-free walking distance, and Wagner stage as well as a reduction in ulcer size" in comparison with the single-injected CLI patients (Zafarghandi et al., 2010). However, it should be noted that the BM-MNCs are also showing satisfactory efficacy in ischemic limb regeneration (**Supplementary Table S1**). The achievement, compared to the other heterogeneous and high-potent stem cell populations with a suitable regenerative potential, can be presented as an effective approach along the lines of managing limb ischemia regeneration.

Mesenchymal Stem Cells

Based on several hypotheses, presenting a large level of MSCs into the BM-MNC population introduces a key method in order to manage an effective therapeutic strategy for the regeneration of ischemic disorders (Wang et al., 2018; Khodayari et al., 2019; Mardanpour et al., 2019). Moreover, among the BM-MNC cellular population, the MSCs have shown more effectiveness for improving the ischemic limb tissues based on the particular observations in comparison with the other stem cells (Mafi et al., 2011; Gupta et al., 2013). In addition to the bone marrow, the MSCs can be isolated from different origins like fatty pads, synovium, and cord blood (Khodayari et al., 2019). Secreting a high level of paracrine factors, increased proliferation and differentiation potential, ability to utilize as an allogeneic source, elevated resistance to inflammation as well as lower teratogenic/carcinogenic potential considers the main advantages of the MSCs for the regenerating targets (Khodayari et al., 2019; Khalighfard et al., 2021). In contrast, the requirement to use invasive methods for getting a biopsy sample, the dependence of the cells' proliferative and differentiation capacity with age, and the need to use various markers for producing a homogeneous population are the cells' main disadvantages (Matsiko et al., 2013). Phenotypically, in humans, the BMSCs are a fibroblast-like cell population that is generally distinguished by the positive expression of STOR1, CD73, CD90, and CD105, besides the negative expression of CD11b, CD14, and CD34. Also, as negatively marked, CD79a and HLA-DR can be noticed in the MSCs (Khodayari et al., 2019). In addition to the bone marrow, human MSCs can be isolated from different niches, including the adipose tissue (Yañez et al., 2006), umbilical cord blood (Hong et al., 2005), and dental tissue (Xu et al., 2020).

There are several successful clinical methods for evaluating the regenerative impacts of MSCs on limb ischemia disorders. Gupta et al. (2013) have shown that intramuscularly injected BM-MSCs not only were safe but also decreased the CLI patient's limb pain and improved their ABI and ankle brachial pressure index (ABPI). Also, they have shown that the numbers of the administrated CM-MSCs are able to positively change the cell therapy output in CLI cases (Gupta et al., 2013). Das et al. (2013), *via* an intra-arterial allogeneic MSC infusion into CLI patients, could recognize a safe and effective response in their study. Based on their reports, not only did the MSCs treated group show




FIGURE 2 | Outcome of simultaneous autologous BM-MNC and G-CSF administration to patients with limb ischemia. **First part:** a brief representation of the flowchart for the clinical trial design and assessments. The study was a phase I randomized controlled trial on fifteen patients with severe CLI. The intervention's safety and efficacy were evaluated by laboratory analysis, clinical evaluation, and imaging. **Second part: (A)** qRT-PCR analysis of the expression of angiogenesis markers in two arms, BM-MNC alone vs. BM-MNC plus G-CSF. **(B)** Improvement in limb salvage after autologous BM-MNC therapy. Zafarghandi, Mohammad Reza, et al. *Cytotherapy* 12.6 (2010): 783–791.

significant pain relief, but it also greatly improved the other clinical indexes, including the visual analog scale (VAS), ABPI, and transcutaneous oxygen pressure (TcPO₂) (Das et al., 2013). Other clinical observations have only shown an unstable and limited regeneration response from the MSC subtype implant. Adipose-derived stromal/stem cells (ADSCs) are introduced as a mesenchymal stem-like population with the same molecular phenotype as MSCs (Zannettino et al., 2008). Moreover, Bura et al. (2014), through their phase I clinical trial on nonrevascularizable CLI patients, observed that even though intramuscularly injected ADSCs in the ischemic tissue were feasible and safe, the case's clinical index was not sufficiently improved after the cell therapy (Bura et al., 2014). This variation and huge difference between the MSCs and the MSC-like regenerative responses may be dependent on the variations of the cell's niches, paracrine/autocrine activity, and differentiation potential.

Generally, stimulating the angiogenic mechanisms in the MSCs seems to be a powerful approach for improving the

neovascularization response from the implanted MSCs (Yu and Dardik, 2018; Goodarzi et al., 2020; Khalighfard et al., 2021). The upregulation of hypoxia-inducible transcription factor-1α (HIF-1α), as a chief angiogenic regulator, could be used as a feasible and effective procedure that could achieve this result. During this process, as the main downstream target of HIF-1α, activation of remarkable angiogenic signaling pathways including the vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), transforming growth factor-β (TGF-β), and small mothers against decapentaplegic 3/4 (SMAD 3/4) can greatly improve the human MSCs' endothelial differentiation in the ischemic limb microenvironment (Huang et al., 2016). This hypothesis has been successfully proven by Wang et al., 2015), following their preclinical observations (Huang et al., 2016). Through intramuscular injection of 1×10⁶ HIF-1α upregulated human MSCs, they recorded a meaningful angiogenic response and observed the injured limb tissue regenerate early after the cell transplantation (Howangyin et al., 2014).

CD34-Positive Mononuclear Cells

As a population of MNCs, the CD34⁺ mononuclear cells present a non-hematopoietic stem cell with an innate potential for tissue regeneration (Johnson et al., 2020). Different origins such as umbilical cord blood, bone marrow, and peripheral blood are utilized for the isolation of high-potent CD34⁺ MNCs to be used as a therapeutic factor (Bender et al., 1994; Johnson et al., 2020). In this case, BM and PB-CD34⁺ MNCs are the most commonly trialed cells for the treatment of ischemic limbs in practice (Supplementary Table S1). Generally, these cells can be isolated by positive expression of CD34 markers along with negative expression of CD14 and CD45 transmembrane proteins (Table 1). Different experimental observations have concluded that the PB-CD34⁺ MNCs could directly generate types of cellular lineages like myocytes (Avitabile et al., 2011), endothelial cells (Krenning et al., 2009), and neural cell lineages (Reali et al., 2006) that are vital for injured limb regeneration. In addition to their differentiation potential, the release of different therapeutic factors, including 1) cytokines and immune suppressors, 2) growth factors and morphogens, 3) chemokines and surface regulatory markers, and 4) extracellular vesicles, can be used as other therapeutic effects resulting from the PB-CD34⁺ MNCs implantation. A list of the main PB-CD34⁺ MNCs secretomes is categorized in Table 1.

In order to increase the mobilization of the CD34⁺ MNCs into circulation, the most common approach is to administer G-CSF days before cell isolation (Kawamoto et al., 2009). It has been shown that the pharmacological effects of G-CSF on BM stem cell populations are directly promoted *via* activation of signal transducer and activator of transcription 3 (STAT3) and rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF) signaling (Kamezaki et al., 2005). These pathways serve as types of central mechanisms which promote cellular proliferation and migration from bone marrow to transmission. So far, different experimental and clinical trials have evaluated the safety and effectiveness of the PB-CD34⁺ MNCs in the various types of LIs (Kawamoto et al., 2009). Wahid et al. (2018) wrote in their meta-analysis for evaluating the “efficacy and safety of autologous cell-based therapy in patients with no-option critical limb ischemia” that the MNCs, mainly bone marrow-driven cells, are safe stem cells with more therapeutic potential for the regeneration of CLI (Wahid et al., 2018). In one of the earliest clinical trials, Kinoshita et al. (2012) examined the long-term clinical outcome of IM G-CSF-mobilized CD34 MNC injection in patients with CLI (Kinoshita et al., 2012). Their observation demonstrated that the IM injection of PB-CD34⁺ MNCs had favorable and long-term clinical benefits in these types of patients. As a result, they have recorded an improvement in brachial pressure index and transcutaneous partial oxygen pressure up to 6 months after cell therapy (Kinoshita et al., 2012).

It seems that in addition to using a sufficient number of a viable and homogenous population of CD34⁺ MNCs, the characteristics of subjects can be a determining issue for performing efficient cell therapy in LI patients. Pan et al. (2019), phase I/II clinical trial, showed that the total number of transplanted cells, patient’s age, blood fibrinogen, arterial

occlusion level, and TcPO₂ directly affected the outcome of PB-CD34⁺ MNCs therapeutic angiogenesis for no-option CLI cases (Pan et al., 2019). Moreover, the different observations identified suitable outcomes of the PB-CD34⁺ MNC therapy in CLI patients with atherosclerotic peripheral arterial disease and Buerger’s disease (Supplementary Table S1).

Endothelial Progenitor Cells

Endothelial progenitor cells (EPCs) have been utilized to generate various cell types that have a key role in endothelial lining regeneration and neovascularization (Esquivia et al., 2018). Generally, EPCs are generated in the bone marrow environment by the CD34⁺/CD45⁺/CD133⁺ hematopoietic stem cells (HSCs) and non-hematopoietic bone marrow cells, including the MSCs (Urbich and Dimmeler, 2004). EPCs are collected within the positive expression of CD133, CD34, and vascular endothelial growth factor receptor-2 (VEGFR2) directly from the bone marrow or circulating blood cells (Urbich and Dimmeler, 2004; Friedrich et al., 2006). It has been reported that in addition to neovascularization into the injured tissues, utilized EPCs can modulate the stressful organ’s microenvironment through expression of diverse types of angiogenic growth factors like VEGF, hepatocyte growth factor (HGF), and insulin-like growth factor 1 (IGF-1) (Abe et al., 2013).

In the past, some clinical observations have considered the use of EPC’s regenerative potential for patients with limb ischemia. As a primer clinical observation, Kudo et al. (2003) stated that intramuscular injection of the autologous CD34⁺ EPC can be a powerful method for regenerating ischemic limb tissues. The results they presented after EPC therapy read “transcutaneous oxygen pressure in the foot increased and clinical symptoms improved.” Newly visible collateral blood vessels were directly documented by angiography (Kudo et al., 2003). The important physiological function of the EPCs on the limb ischemia patient’s therapeutic response rate has already been discovered. Based on this hypothesis, the lower neovascularization rate into the limb ischemia patients who are showing a minor therapeutic response to the treatments may be related to their EPC defect. Flow cytometry and EPC quantitative molecular analysis on ischemic limbs patients with a moderate risk of neovascularization, showed that not only the number of their circulating EPCs was lower but also the proliferation and differentiation potential of their collective EPCs was not as high as it was in the control cases (Yamamoto et al., 2004).

It has been found that stimulation of the EPCs with pro-inflammatory cytokines, like IL-1 β , IL-3, and TNF- α , significantly decreases the proliferation and angiogenic potential of the cell. Accordingly, to perform an effective cell therapy on the ischemic limbs, based on using the EPCs, production of them at a large level are required (Peplow, 2014). We believe that this is the main disadvantage that leads to the reduction of this regenerative method’s cost-effectiveness.

Neural Stem Cells

Peripheral neuropathy associated with limb ischemia is one of the prevalent pathogenesis that is commonly observed in patients with vascular disease (Uccioli et al., 2018). “Chronic pain, foot

ulcers, foot infections, and amputations” manifest as chief complications caused by peripheral neuropathy (Hicks and Selvin, 2019). Nowadays, using stem cell technology for regeneration of the damaged peripheral neural system (PNS) presents an applicable, safe, and efficient method (Sullivan et al., 2016). This discovery of NSCs was an impactful development for the sake of eventually achieving a regenerative method for the injured PNS. The NSCs are a population of undifferentiated cells that naturally persist in the mammalian ventricular-subventricular zone (V-SVZ) and the subgranular zone (SGZ) (Fuentealba et al., 2012). In humans, this cellular population is noted by positive expression of CD184, CD24, nestin, fibroblast growth factor receptor (FGF-R), glial fibrillary acidic protein (GFAP), SRY-box transcription factors 1/2 (SOX1/2), forkhead box O3 (FOXO-3), and orphan Nuclear Receptor TLX, as well as negatively expressed CD271 and CD44 markers (Table 1). Different observations proved the neural lineage differentiation potential of NSCs in both *in vitro* and *in vivo* conditions (Harbom et al., 2018). In addition to the release of various paracrine and growth factors, these stem cells can also express types of chemokines and cell migration receptors (Table 1).

The large-scale production of NSCs for managing an effective cell therapy in patients with PNS disorders presents a principal challenge. Extreme risks of taking a biopsy from a patient's SVZ and SGZ, the presence of small numbers of NSCs in the received tissue, and finally, the poor proliferative potential of the hNSCs primary cultures are some of the limitations presented in this approach (Kaneko et al., 2011). However, like the EPCs, resistance to the ischemic organ inflammatory responses along with the high cost of the NSCs' isolation, culture, and purification prevents the widespread use of these cells in the practice (Pluchino et al., 2020). Nowadays, using gene transfection technology to generate off-the-shelf NSCs lines serves as a feasible and satisfactory approach. As a pioneer product, the human NSC-line CTX (CTX0E03) created with the MYCL proto-oncogene (c-myc)-ERTAM transfection performs as an off-the-shelf allogeneic stem cell for the CNS and PNS regeneration targets, in practice (Yoon et al., 2020). Results of the Muir et al. (2020) clinical trial on twenty-three patients with stroke confirmed that intracerebral implantation of the CTX cells was not only a feasible approach for nerve regeneration but also had a positive outcome on the subject's motor recovery up to 12 months after implantation (Muir et al., 2020). A phase I, randomized, controlled trial has been launched in order to investigate the safety of CTX0E03 cell line implantation in patients with “insulinized diabetic patients type 2 with CLI in the lower limb” (ClinicalTrials.gov Identifier: NCT02287974). Although results have yet to be posted from this ongoing study, evidence raised from Muir et al. (2020) study may suggest that using these universal cell lines could be a safe and efficient cell therapy method for patients with LI.

ENDOMETRIAL-DERIVED STEM CELLS: ALL-IN-ONE FOR LIMB REGENERATION

As we explained, different stem cells have been utilized in many preclinical and clinical experiments over the past 5 decades due to

their extraordinary capacity for differentiation into multiple lineages, immunomodulation, and angiogenic properties (Supplementary Table S1). During the past few years, our team's extensive observations into EnSCs have displayed this stem cell's potential for regenerating ischemic organs as well as limb tissue. The presence of stem cells in the endometrium was first speculated upon by Prianishnikov (1978) (Prianishnikov, 1978). Chan et al. (2004) also confirmed the presence of clonogenic stem cell populations in the endometrium tissue (Chan et al., 2004). We already proved that this mentioned regenerative capacity in the endometrium tissue is due to the presence of EnSCs that were demonstrated to be immunoprivileged in comparison with other cell types (Shamosi et al., 2015), shedding new light on cell-based therapies and rendering these cells a promising resource in limb tissue regeneration (Figure 3). The human endometrium is a highly regenerative tissue due to the fact that a complete regeneration of the uterus can be achieved after almost total resection of the endometrium, with the renovated endometrium still maintaining its ability to support gestation (Murphy et al., 2008). Monthly cyclical endometrial growth, differentiation, and regression are governed by a fine-tuned interplay between ovarian sex steroid hormones and numerous cell types. It has been shown that estrogen replacement therapy can regenerate atrophied endometrium (Evans et al., 2016). The endometrial tissue is composed of epithelial stem cells (0.22%), mesenchymal stem cells (1.25%), and side population stem cells (Sasson and Taylor, 2008). During menstruation, all of these cells could be found as menstrual stem cells or endometrial regenerative cells (ERC) (Verdi et al., 2014). Like the other sources, endometrial MSCs have recently emerged as a promising alternative source of therapeutic MSCs due to their unique ability to undergo smooth muscle differentiation (Rink et al., 2017), angiogenic (Cabezas et al., 2018), adipogenic (Ye and Yuan, 2007) and robust immunomodulation properties (Cortés-Araya et al., 2018). *In vitro* analysis reported that the EnSCs positively express stage-specific embryonic antigen-4 (SSEA-4) (and octamer-binding transcription factor 4 (OCT4) markers and decrease OCT4 expression with increasing passages that confirm its stemness (Piccinato et al., 2015). The EnSCs also expressed high levels of CD73, CD90, CD105, and CD166, but they lacked CD14, CD34, and CD45 expression, which are very similar to the minimum characteristics of MSCs defined by the committee of the International Society for Cellular Therapy (Piccirillo et al., 2013). The EnSCs also have a high proliferation, multidirectional, and differentiation capacity that is indicative of the potential for tissue regeneration (Ai and Ebrahimi, 2010).

As an advantage, the EnSCs have been shown to have the same immunophenotype as the MSCs. These cells express MHC class I (HLA-ABC) but not MHC II (HLA-DR). They have the capability to modulate immune system functions, reduce proinflammatory cytokines including the TNF- α and interferon gamma (IFN- γ), and have been shown to inhibit mixed lymphocyte reactions (MLR) in different experiments (Cheng et al., 2017). As a result, EnSCs have been shown to have low immunogenicity and various *in vivo* experiments




FIGURE 3 | Schematic representation of the endometrial stem cells possible impact on the limb ischemia regeneration subjects. The endometrial stem cells can be directly isolated from an endometrium biopsy through exposure of endometrial, mesenchymal, and endothelial specific markers. It seems that implantation of the *in vitro* expanded endometrial stem cells into the ischemic regions is able to protect the damaged cells from cellular death through a powerful paracrine/autocrine activity. In addition to, as a multipotent stem cell, the endometrial stem cells can generate the main limb lineage cells, which may promote effective regeneration in the ischemic limbs. Figure created with BioRender.com.

have been performed without the occurrence of immune rejection (Giudice, 1994). Moreover, as well as the MSCs, the EnSCs can directly synthesize and discharge several types of paracrine factors, including the TGF α , EGF, and IGF-I (Figure 3). IGF-I, TGF α , epidermal growth factor receptor (EGFR), basic fibroblast growth factor (bFGF), and platelet-derived growth factor- β (PDGF β) receptor, which are expressed in epithelial cells, are upregulated during expeditious growth in the proliferative stage of stem cells. Leukemia inhibitory factor (LIF), hepatocyte growth factor (HGF), and stem cell factor (SCF) have an essential contribution to endometrial regeneration (Chegini et al., 1992). All of the EnSC paracrine factors have an essential role in ischemic limb regeneration.

The novel hypothesis considers angiogenesis as the most remarkable regenerative approach, along with stem cell therapy for limb ischemia patients. We strongly believe, due to the high similarity between the EnSCs and the MSCs, that evaluating the MSCs' angiogenic responses in the ischemic tissue's microenvironment can be an accurate model to study for the EnSCs' angiogenic behaviors (Ai and Ebrahimi, 2010). The MSCs exhibit angiogenic properties by not only paracrine signaling but also by regulating this response through direct cellular involvement. An array of angiogenic factors secreted by MSCs, for example, VEGF, SDF1, FGF2, HGF, angiopoietin-1 (ANG1), and monocyte chemoattractant protein-1 (MCP-1), act as key growth factors for primary vessel formation and its stabilization (Tao et al., 2016).

Moreover, *in vitro* and *in vivo* studies showed that the microvesicles (>200 µm) and exosomes (~50–200 µm) secreted by MSCs transport proangiogenic growth factors and miRNA (Phinney and Pittenger, 2017). A proteomic analysis showed that enhanced therapeutic angiogenesis, resulting from the secretion of MSC-derived exosomal proteins (PDGF, FGF, EGF, NF-κB pathway-affiliated proteins, etc.) into the ischemic region, has been observed after MSC therapy (Anderson et al., 2016). X.Liang T. W. et al., 2016) demonstrated that adipose MSC-derived exosomes transfer miR-125a to endothelial cells and promote angiogenesis (Liang X. et al., 2016). Also, Gong et al. (2017) have investigated whether the proangiogenic exosomal miRNA (miR-424, miR-30c, miR-30b, let-7f, etc.), derived from MSCs, can be transferred into endothelial cells (Gong et al., 2017).

Many investigations have shown that BM-MSCs have a strong capability for angiogenesis induction (Kinnaird et al., 2004). Clearly, the EMSCs and BM-MSCs share some common cell surface markers like CD90 and CD105, while lacking CD45 and CD34 (Keating, 2012). A series of experiments have been performed *in vitro* and *in vivo* to assess the proof of an angiogenic concept on endometrial derived stem cells, and they showed that EnSCs could stimulate angiogenesis (Murphy et al., 2008). Results from our team's studies have shown that human EnSCs could proliferate and sprout new blood vessels in 3D fibrin matrix supported culture (Esfandiari et al., 2007a; Esfandiari et al., 2007b; Esfandiari et al., 2008). Similarly, in 2013, we were able to prove the EnSCs' direct potential to generate CD34⁺ endothelial cells (Ai et al., 2013). In addition, according to data from one of our *in vitro* experiments, human EnSCs have shown that they can be differentiated into endothelial-like cells in the presence of FGF-2 and VEGF on a nanofibrous scaffold (Shamosi et al., 2017). Following this discovery, in 2004, we demonstrated the vascular network formation and the angiogenic potential of EnSCs through an *in vitro* examination (Esfandiari et al., 2008). It is important to note that EnSCs are found to be clonogenic mesenchymal-like cells (Gargett et al., 2009), which express pericyte markers and are localized in the perivascular space of endometrial small vessels (Berger et al., 2005). These cells play a central role in the formation of endometrial stromal vascular tissue and vascularization through the secretion of pro-angiogenic and growth-supporting factors. Canosa et al., 2017) concluded that the EnSCs could support the endothelial cell's ability to differentiate by taking information from the endothelium and new blood vessels (Canosa et al., 2017). Due to these findings, we believe that the EnSCs can be considered as an impactful stem cell for managing effective regenerative angiogenesis in the injured limb tissue microenvironment (Figure 3).

Aside from angiogenesis, reconstructing the failed myocytes into the ischemic limb area is introduced as another target along with limb tissue regeneration. In this regard, our team's remarks claimed that the EnSCs seem to be a suitable cellular source for regulating myogenesis in addition to the other well-trialed sources like the MSCs. Various experimental study showed that MSCs could differentiate into skeletal muscle cells and could be a feet source for repair (Gang et al., 2004; Sassoli et al., 2014). Gang et al. (2004) isolated MSCs from umbilical

cord blood and induced them to differentiate into skeletal muscle cells. They recommended this stem cell phenotype as a useful tool for muscle-related tissue engineering (Gang et al., 2004). A few years later, Toyoda et al. (2007) described the EnSCs derived from menstrual blood have the remarkable myogenic potential that could allow "rescue" dystrophied myocytes in the MDX model through cell fusion and transdifferentiation (Toyoda et al., 2007). In their work, Cui et al. (2007) showed that endometrial progenitors and menstrual blood-derived mesenchymal stem cells could efficiently transdifferentiate into myoblasts/myocytes, both in *in vitro* and *in vivo* experiments. They expected that the EnSCs could be a major advancement toward cell-based therapies for chronic muscular diseases and muscle injury (Cui et al., 2007). However, based on our investigations, we have a more transcendent view of EnSCs as a powerful tool for myocyte regeneration. In 2009, we carefully hypothesized that EnSCs could be a more suitable option for muscle regeneration cell therapy, based on the properties of EnSCs, including easy accessibility, easy purification, clonogenicity, and maintenance of normal karyotyping in extended passages (Cui et al., 2007). Also in 2014, one of our lab's investigations showed that the EnSCs could serve as a potent myogenic cell source, having a superior differentiation capacity over that of BM-MSCs that was fully supported by Real-Time polymerase chain reaction (PCR) and immunocytochemistry to detect myogenic markers and quantitative-PCR for the upregulation of desmin, myoblast determination protein 1 (MyoD), and troponin T transcripts (Faghihi et al., 2014). All the presented pieces of evidence illustrate that the EnSCs could serve as a proper target for achieving an effective myogenic response in the ischemic limb tissue like the MSCs (Figure 3).

The stressful conditions that form early after ischemia has been able to cause cellular death cascades in all limb cell populations as well as neurons. Recreating the degenerated PNS within patients with a large limb injury could be an impactful method for recovering their lost limb functions. This cell therapy research has been focusing on finding a suitable source of stem cells to regenerate the PNS after limb ischemia. Considering the ethical grounds, purity, viability, and tumorigenicity, EnSCs can potentially be a promising source of easily accessible, substantial, and multipotent adult stem cells. In this endeavor, the EnSCs could be used as an alternative source (Figure 3). It is well understood that human EnSCs have provided new and effective approaches for neural cell programming. Our experiments reported that neuron-like cells were differentiated from EnSCs by different *in vitro* methods (Navaei-Nigjeh et al., 2014; Mirzaei et al., 2016; Hasanzadeh et al., 2021).

During the course of their research, Meng et al. (2007) have shown that the EnSCs, during their neurogenic differentiation, could express cytoskeletal proteins that include neurofilament-light (NF-L), class III b-tubulin (b3-tub), microtubule associated protein 2 (MAP 2), and oligodendrocyte transcription factor 1 (olig1) as mature markers in the differentiated neuronal-like cell (Meng et al., 2007). Moreover, in 2012, we were able to successfully make neuronal-like cell phenotypes from the EnSCs. Our flow cytometric analysis demonstrated the positive

expression of cell surface markers including CD90, CD105, OCT4, CD44, and negative for CD31, CD34, and CD133. Moreover, our q-PCR and immunocytochemistry evaluation shown expression of the nestin, c-aminobutyric acid (GABA), MAP2, class III β -tubulin (b3-tub), and neurofilament light polypeptide (NF-L) in the EnSCs (Mobarakkeh et al., 2012). Following our subsequent projects, Ebrahimi-Barough et al. (2013a) could generate oligodendrocyte progenitor cells (OPCs) from human EnSCs and Asmani et al. (2013) differentiated the OPCs in a 3D culture system (fibrin hydrogel) from EnSCs (Ebrahimi-Barough et al., 2013a; Ebrahimi-Barough et al., 2015). Due to these results, we hypothesized that the activation of the miR-338 cascade plays a central role in the generation of oligodendrocyte cells from the EnSCs (Ebrahimi-Barough et al., 2013b).

To further our studies, we carefully investigated and compared the differentiation potential of the BMMSC and EnSCs to motor neuron-like cells on a nanofibrous scaffold (poly ϵ -caprolactone) using signaling molecules. Immunostaining and real-time PCR demonstrated expression of beta-tubulin III, islet-1, motor neuron and pancreas homeobox 1 (MNX1), neurofilament-H (NF-H), paired box 6 (Pax6), and choactase-positive motor neurons. We finally concluded that both cells had potential in the differentiation of motor neuron-like cells, but EnSc was superior to BM-MSC (Shirian et al., 2016). During the course of the study, our team was able to differentiate Schwann cells from EnSCs for the first time, using fibrin gel as a 3D culture environment by induction media. Immunocytochemistry confirmed the indicative markers (S100 and P75) for Schwann cells (Bayat et al., 2016). Also, our more recent *in vivo* examination of animal models with PNS disorders (sciatic nerve injury) demonstrated nerve regeneration in rats after the sciatic transaction followed by human EnSCs treatment in a defined nanofiber conduit (Mohamadi et al., 2018). As a result, the motor and sensory integrity were significantly improved in EnSCs-treated animals. All the pieces of evidence given before are able to display the feasibility and efficacy of the EnSC therapy to regenerate the injured limb's PNS networks (Figure 2).

CHALLENGES AND SOLUTIONS

In an effort to develop a more efficient method of stem cell transfusion, scientists have spent more than 13 years doing clinical research on the subject (Lobo et al., 1991). After numerous observations, trial-and-error, and analysis, we have finally reached a breakthrough for stem cell-based therapy approaches, mainly for ischemic disorders. Proper understanding of the most common barriers and challenges is key to achieving an effective stem cell therapy method that could assist in the regeneration of ischemic regions. Based on our experience, these aforementioned barriers can be summarized into three separate steps: 1) stem cell manufacturing, 2) choosing the fittest stem cells based on disease characteristics, and 3) mechanisms of ischemia pathogenesis. In this section, we focus on these main challenges and then explain some practical solutions for overcoming those


challenges. Figure 4 briefly displays the different limitations of ischemic disorder stem cell therapy and presents some efficient solutions for each issue (Figure 4).

Stem Cells Manufacturing

Nowadays, developing technologies for the large-scale production of viable stem cells, and/or cellular products is a determining factor for the expansion of stem cell-based therapy in practice (Ausubel et al., 2011). Utilizing these types of technologies not only has a positive impact on reducing the price of cell therapy for each case, but can also be a solution to overcome ethical and logistical issues found with autologous stem cell therapies (Ausubel et al., 2011). Assuring good quality standards for biopharmaceutical production is done by following the good manufacturing practice (GMP) regulations (Jo et al., 2020). Accordingly, the GMP standards must be considered when manufacturing different cell products, including stem cells and differentiated cells. In this regard, GMP's quality management system is largely used to monitor all the phases of the biopharmaceutical manufacturing process. Based on the GMP instructions, the purpose of the quality control (QC) section of a medical production factory is to guarantee product quality. It is based on a clear association between accurate assessment and critical quality features of the product of interest, including having an identity, being safe, pure, and potential (Viganò et al., 2018). Particular guidelines like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) identify and explain the as-mentioned matters (Halme and Kessler, 2006; Emea, 2008). Some crucial steps in safety assessments are the evaluation of any microbial contamination (viral, bacterial, and fungal), teratogenic potential, and any biological abnormality in the final cell product (Viganò et al., 2018). These types of accurate quality controls and potentiometry of cell products make GMP guidelines a very powerful tool for the production of safe and efficient stem cells for a cost-effective stem cell therapy approach.

Selection of an Efficient Stem Cell Type

Identifying and utilizing the most proper types of stem cell production, dosage, and implantation methods is another main issue for managing effective stem cell therapy in ischemic tissues. Achieving this mentioned target is directly related to having a suitable awareness of the ischemia intensity, phase of inflammatory reactions, reperfusion status, and several additional characteristics that appear in ischemic organs (Khodayari et al., 2019). After reviewing the collected information that can be found in **Supplementary Table S1**, it is hypothesized that this recorded controversial outcome, resulting from the stem cell administration, may be linked with a shortage of accurate awareness of the disease status and its possible feedback on the implanted cells. Nowadays, guideline-based medicine has become the mainstay of ischemia treatment (Zabel et al., 2020). Presenting these types of practical, evidence-based guidelines for stem cell therapy of ischemic disorders can be a solution to overcoming this challenge. The availability of clinical data, in particular from randomized controlled clinical trials (RCTs) for a specific query generally leads to the guidelines with overwhelming evidence (de



Clercq, 2003). Concisely, the RCTs of ischemia stem cell therapy should meet inclusive and exclusive requirements. These criteria provide a wide and enriched study population, leading to expected goals along with different results from statistical and clinical points of view (Burns et al., 2011). Subgroup analyses on the predetermined ones and other post hoc analyses can assist with the identification of the features linked with more advantages, without benefit or damage from stem cell-based therapy, in the study population (Tanniou et al., 2016). So far, the FDA has released some guidelines for cellular and gene therapy approaches (Corsaro et al., 2021); however, none of them refer to ischemia disease treatments. Presenting an evidence-based guideline in order to administer the most efficient stem cell therapy treatment based on the patient’s characteristics can be an evolutionary achievement in the field of cell therapy for ischemic diseases.

Ischemia Pathological Mechanism Adverse Effects

The process of ischemia pathogenesis explains a complex and dynamic biological mechanism that eventually terminates in organ familiarity and dysfunction, as we previously explained

in section one, “limb ischemia pathophysiology: pathways and mechanisms.” In this regard, the formation of these types of complex biological reactions following ischemia disrupts the implanted stem cells (Khodayari et al., 2019). That means that the development of these mechanisms will not only promote cell death and tissue degeneration in the ischemic organ but can also have a negative biological effect on the implanted cells. In 2019, we hypothesized that the creation of an intense inflammatory response during the acute phase of myocardial ischemia can be a confounding factor in the reduction of efficacy for cell therapy in patients with acute myocardial infarction. Hence, employing types of efficient paraclinical testings in order to obtain an accurate recognition of the disease features and failure characteristics can be an effective approach in future cell therapy measures. In addition to this approach, reducing inflammation before cell therapy as well as stem cell concomitant injection with anti-inflammatory drug therapy or cells with immunoregulatory potential, like MSCs, can be an efficient approach to solving this challenge (Khodayari et al., 2019).

Instead of direct implantation of stem cells, it has been suggested that using extracellular vesicles (exosomes) can be a

new perspective on regenerative medicine and cell-free therapy in ischemia subjects with active inflammation (Anderson et al., 2016; Liang X. et al., 2016; Phinney and Pittenger, 2017). This type of stem cell product is entirely resistant to inflammation pathogenesis (Xia et al., 2019). Direct cell-cell micro-communication is commonly mediated by exosomes through the use of critical functional molecules including nucleotides, proteins, as well as bioactive lipids. Different SCs, for instance, MSCs, secrete the as-mentioned small membrane vesicles (30–100 nm) (Anderson et al., 2016; Liang X. et al., 2016; Phinney and Pittenger, 2017). It is believed that healing after myocardial infarction might be regulated by MSCs-secreted exosomes. A research study was conducted on rat models with acute myocardial infarction (AMI) and proved that MSC-derived exosomes improve the function of the myocardium just after heart injury. This is related to inflammatory microenvironment reprogramming in AMI. Our *ex vivo* investigation in 2019 has suggested that the EnSCs-derived exosome could regulate angiogenesis and vessel formation in the endothelial progenitor cells (Taghdiri Nooshabadi et al., 2019). As a result, we found that this EnSCs-derived exosome angiogenic outcome operates by a dosage-dependent action (Taghdiri Nooshabadi et al., 2019), as evidenced by the dual results observed in drugs and agents as well as atorvastatin (Goodarzi et al., 2020). In summary, once EnSC-derived exosomes hold biological effects similar to their source cells, they could be deemed as new, cell-free, therapeutic candidates. Generally, as angiogenesis increases, the exosomes derived from EnSC indicate the possibility for use in regenerative medicine, particularly for ischemic disorders (Taghdiri Nooshabadi et al., 2019). So far, in addition to targeting treatment of acute ischemic stroke (NCT03384433), different clinical studies have been launched to evaluate the safety and efficacy of stem cell-derived exosomes on different disorders like acute respiratory distress syndrome (NCT04602104, NCT04798716), depression, anxiety, dementias (NCT04202770), periodontitis (NCT04270006), and metastatic pancreas cancer (NCT03608631).

CONCLUSION AND FUTURE PERSPECTIVE

Destruction of all cellular populations soon after the initiation of ischemia is an inevitable outcome in the ischemic limb regions. Recreation of vascular networks in a stressed tissue or organ is introduced as the first line of stem cell therapy for these patients. However, it appears that through neovascularization, improving blood circulation is not therapeutic enough to recover the ischemic limb function. Theoretically, utilization of a safe stem cell variety with the potential to generate other limb tissue's cellular niches in addition to the endothelial cells, such as the myocytes and PNS cells, dramatically enhances the stem cell therapy effectiveness to promote the limb ischemia patient's function. According to these criteria, although stem cell

therapy has offered a closely acceptable output in various experimental and clinical trials, taking advantage of new and more proper stem cell sources will provide us with a suitable treatment for injured limb regeneration. Throughout the last decade, our lab's efforts were to clarify the EnSCs' biology and regeneration potential for improving several degenerative disorders. We remark that although the EnSC niche is derived from an inappropriate tissue, the high potential to generate an array of cellular populations alongside their low immunogenicity will make this lineage a new source of LI regeneration. Using this method, designing translational studies and then measuring the direct regenerative effects of EnSCs on the failed limb are one of our main approaches. However, different limitations and unsolved barriers prevent us from performing an effective regeneration therapy on ischemic diseases using life and autologous stem cells. Nonetheless, to overcome this challenge, researchers should move to develop modern approaches according to prior experiences. It seems to be an adequately safe, efficient, and cost-effective regeneration therapy method for different types of human disorders by: 1) designing a practical evidence-based guideline for stem cell administration, 2) utilizing next-generation regenerative methods, including off-the-shelf universal stem cell and cell-free exosome therapy, and 3) moderating the ischemic limb tissue inflammatory response before cell injection by using common therapeutics seems to be an adequately safe, efficient, and cost-effective regeneration therapy method for different types of human disorders.

AUTHORS CONTRIBUTIONS

Study design: SK, HK, SE-B, MK, and NA. Conceptualization/original draft preparation: SK, HK, MI. Graphical art works and tables: SK and HK. Review and editing: SE-B, MK, MV, AG, KN, and HM. Review, editing, and supervision: NA and JA.

FUNDING

This work was supported by the Tehran University of Medical Sciences (Projects Code: 99-1-115-47842; 1400-2-259-54530).

ACKNOWLEDGMENTS

Schematic representations were generated in “BioRender.com” and “CorelDRAW Graphics Suite X8” (version 2018).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcell.2022.834754/full#supplementary-material>

REFERENCES

- Abe, Y., Ozaki, Y., Kasuya, J., Yamamoto, K., Ando, J., Sudo, R., et al. (2013). Endothelial Progenitor Cells Promote Directional Three-Dimensional Endothelial Network Formation by Secreting Vascular Endothelial Growth Factor. *PLoS One* 8, e82085. doi:10.1371/journal.pone.0082085
- Ai, J., Ebrahimi, S., Ai, A., Karimi, R., and Bahrami, N. (2013). Effect of Deforolimus and VEGF on Angiogenesis in Endometrial Stromal Cells Following Three-Dimensional Culture. *Stem Cell Discov.* 3, 73–75. doi:10.4236/scd.2013.31002
- Ai, J., and Ebrahimi, S. (2010). Are Endometrial Stem Cells Novel Tools against Ischemic Heart Failure in Women? a Hypothesis. *Iranian Red Crescent Med. J.* 12. doi:10.4236/scd.2013.31002
- Almasri, J., Adusumalli, J., Asi, N., Lakis, S., Alsawas, M., Prokop, L. J., et al. (2019). A Systematic Review and Meta-Analysis of Revascularization Outcomes of Intrainguinal Chronic Limb-Threatening Ischemia. *J. Vasc. Surg.* 69, 126S–136S. doi:10.1016/j.jvs.2018.01.071
- Anderson, J. D., Johansson, H. J., Graham, C. S., Vesterlund, M., Pham, M. T., Bramlett, C. S., et al. (2016). Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via Nuclear Factor-KappaB Signaling. *Stem Cells* 34, 601–613. doi:10.1002/stem.2298
- Ausubel, L. J., Lopez, P. M., and Couture, L. A. (2011). “GMP Scale-Up and Banking of Pluripotent Stem Cells for Cellular Therapy Applications.” in *Human Pluripotent Stem Cells* (Springer), 147–159. doi:10.1007/978-1-61779-201-4_11
- Avitabile, D., Crespi, A., Brioschi, C., Parente, V., Toietta, G., Devanna, P., et al. (2011). Human Cord Blood CD34+ Progenitor Cells Acquire Functional Cardiac Properties Through a Cell Fusion Process. *Am. J. Physiology-Heart Circulatory Physiol.* 300, H1875–H1884. doi:10.1152/ajpheart.00523.2010
- Bagheri, F., Khori, V., Alizadeh, A. M., Khalighfard, S., Khodayari, S., and Khodayari, H. (2016). Reactive Oxygen Species-Mediated Cardiac-Reperfusion Injury: Mechanisms and Therapies. *Life Sci.* 165, 43–55. doi:10.1016/j.lfs.2016.09.013
- Batandier, C., Lerveur, X., and Fontaine, E. (2004). Opening of the Mitochondrial Permeability Transition Pore Induces Reactive Oxygen Species Production at the Level of the Respiratory Chain Complex I. *J. Biol. Chem.* 279, 17197–17204. doi:10.1074/jbc.m310329200
- Bayat, N., Ebrahimi-Barough, S., Ardakan, M. M. M., Ai, A., Kamyab, A., Babaloo, N., et al. (2016). Differentiation of Human Endometrial Stem Cells into Schwann Cells in Fibrin Hydrogel as 3D Culture. *Mol. Neurobiol.* 53, 7170–7176. doi:10.1007/s12035-015-9574-7
- Beeken, L. J., Ting, D. S., and Sidney, L. E. (2021). Potential of Mesenchymal Stem Cells as Topical Immunomodulatory Cell Therapies for Ocular Surface Inflammatory Disorders. *Stem Cell Translational Med.* doi:10.1002/sctm.20-0118
- Bender, J. G., Unverzagt, K., Walker, D. E., Lee, W., Smith, S., Williams, S., et al. (1994). Phenotypic Analysis and Characterization of CD34+ Cells from Normal Human Bone Marrow, Cord Blood, Peripheral Blood, and Mobilized Peripheral Blood from Patients Undergoing Autologous Stem Cell Transplantation. *Clin. Immunol. Immunopathology* 70, 10–18. doi:10.1006/clin.1994.1003
- Berger, M., Bergers, G., Arnold, B., HäMmerling, G. N. J., and Ganss, R. (2005). Regulator of G-Protein Signaling-5 Induction in Pericytes Coincides with Active Vessel Remodeling During Neovascularization. *Blood* 105, 1094–1101. doi:10.1182/blood-2004-06-2315
- Bhansali, S., Dutta, P., Kumar, V., Yadav, M. K., Jain, A., Mudaliar, S., et al. (2017). Efficacy of Autologous Bone Marrow-Derived Mesenchymal Stem Cell and Mononuclear Cell Transplantation in Type 2 Diabetes Mellitus: a Randomized, Placebo-Controlled Comparative Study. *Stem Cell Dev.* 26, 471–481. doi:10.1089/scd.2016.0275
- Bockeria, L., Bogin, V., Bockeria, O., Le, T., Alekyan, B., Woods, E. J., et al. (2013). Endometrial Regenerative Cells for Treatment of Heart Failure: A New Stem Cell Enters the Clinic. *J. Translational Med.* 11, 1–8. doi:10.1186/1479-5876-11-56
- Boulard, C., Philippart, P., Dequanter, D., Corrillon, F., Loeb, I., Bron, D., et al. (2021). Cross-Talk Between Mesenchymal Stromal Cells (MSCs) and Endothelial Progenitor Cells (EPCs) in Bone Regeneration. *Front. Cel. Developmental Biol.* 9, 1251. doi:10.3389/fcell.2021.674084
- Bura, A., Planat-Benard, V., Bourin, P., Silvestre, J.-S., Gross, F., Grolleau, J.-L., et al. (2014). Phase I Trial: The Use of Autologous Cultured Adipose-Derived Stroma/Stem Cells to Treat Patients with Non-Revascularizable Critical Limb Ischemia. *Cytotherapy* 16, 245–257. doi:10.1016/j.jcyt.2013.11.011
- Burns, P. B., Rohrich, R. J., and Chung, K. C. (2011). The Levels of Evidence and Their Role in Evidence-Based Medicine. *Plast. Reconstr. Surg.* 128, 305. doi:10.1097/prs.0b013e318219c171
- Cabezas, J., Rojas, D., Navarrete, F., Ortiz, R., Rivera, G., Saravia, F., et al. (2018). Equine Mesenchymal Stem Cells Derived from Endometrial or Adipose Tissue Share Significant Biological Properties, but Have Distinctive Pattern of Surface Markers and Migration. *Theriogenology* 106, 93–102. doi:10.1016/j.theriogenology.2017.09.035
- Cancelas, J., Querol, S., Canals, C., Picon, M., Azqueta, C., Sola, C., et al. (1998). Peripheral Blood CD34+ Cell Immunomagnetic Selection in Breast Cancer Patients: Effect on Hematopoietic Progenitor Content and Hematologic Recovery after High-Dose Chemotherapy and Autotransplantation. *Transfusion* 38, 1063–1070. doi:10.1046/j.1537-2995.1998.38111299056318.x
- Canosa, S., Moggio, A., Brossa, A., Pittatore, G., Marchino, G., Leoncini, S., et al. (2017). Angiogenic Properties of Endometrial Mesenchymal Stromal Cells in Endothelial Co-Culture: an *In Vitro* Model of Endometriosis. *MHR: Basic Sci. Reprod. Med.* 23, 187–198. doi:10.1093/molehr/gax006
- Chan, R. W., Schwab, K. E., and Gargett, C. E. (2004). Clonogenicity of Human Endometrial Epithelial and Stromal Cells. *Biol. Reprod.* 70, 1738–1750. doi:10.1095/biolreprod.103.024109
- Chegini, N., Rossi, M. J., and Masterson, B. J. (1992). Platelet-Derived Growth Factor (PDGF), Epidermal Growth Factor (EGF), and EGF and PDGF Beta-Receptors in Human Endometrial Tissue: Localization and *In Vitro* Action. *Endocrinology* 130, 2373–2385. doi:10.1210/en.130.4.2373
- Cheng, A. J., Yamada, T., Rassier, D. E., Andersson, D. C., Westerblad, H., and Lanner, J. T. (2016). Reactive Oxygen/Nitrogen Species and Contractile Function in Skeletal Muscle during Fatigue and Recovery. *J. Physiol.* 594, 5149–5160. doi:10.1113/jp270650
- Cheng, Y., Li, L., Wang, D., Guo, Q., He, Y., Liang, T., et al. (2017). Characteristics of Human Endometrium-Derived Mesenchymal Stem Cells and Their Tropism to Endometriosis. *Stem Cell Int.* doi:10.1155/2017/4794827
- Cnop, M., Welsh, N., Jonas, J.-C., Jörns, A., Lenzen, S., and Eizirik, D. L. (2005). Mechanisms of Pancreatic β -Cell Death in Type 1 and Type 2 Diabetes: Many Differences, Few Similarities. *Diabetes* 54, S97–S107. doi:10.2337/diabetes.54.suppl_2.s97
- Corsaro, B., Yang, T.-Y., Murphy, R., Sonderegger, I., Exley, A., Bertholet, S., et al. (2021). 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3—Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays). *Bioanalysis* 13, 415–463. doi:10.4155/bio-2021-0007
- Cortés-Araya, Y., Amilon, K., Rink, B. E., Black, G., Lisowski, Z., Donadeu, F. X., et al. (2018). Comparison of Antibacterial and Immunological Properties of Mesenchymal Stem/Stromal Cells from Equine Bone Marrow, Endometrium, and Adipose Tissue. *Stem Cell Dev.* 27, 1518–1525. doi:10.1089/scd.2017.0241
- Cosentino-Gomes, D., Rocco-Machado, N., and Meyer-Fernandes, J. R. (2012). Cell Signaling through Protein Kinase C Oxidation and Activation. *Int. J. Mol. Sci.* 13, 10697–10721. doi:10.3390/ijms130910697
- Cui, C.-H., Uyama, T., Miyado, K., Terai, M., Kyo, S., Kiyono, T., et al. (2007). Menstrual Blood-Derived Cells Confer Human Dystrophin Expression in the Murine Model of Duchenne Muscular Dystrophy via Cell Fusion and Myogenic Transdifferentiation. *Mol. Biol. Cell.* 18, 1586–1594. doi:10.1091/mbc.e06-09-0872
- Curtis, E., Martin, J. R., Gabel, B., Sidhu, N., Rzesiewicz, T. K., Mandeville, R., et al. (2018). A First-In-Human, Phase I Study of Neural Stem Cell Transplantation for Chronic Spinal Cord Injury. *Cell Stem Cell* 22, 941–950. e946. doi:10.1016/j.stem.2018.05.014
- Daltro, G. C., Fortuna, V., De Souza, E. S., Salles, M. M., Carreira, A. C., Meyer, R., et al. (2015). Efficacy of Autologous Stem Cell-Based Therapy for Osteonecrosis of the Femoral Head in Sickle Cell Disease: A Five-Year Follow-Up Study. *Stem Cell Res. Ther.* 6, 1–18. doi:10.1186/s13287-015-0105-2
- Das, A. K., Abdullah, B. J. J. B., Dhillon, S., Vijanari, A., Anoop, C., and Gupta, P. K. (2013). Intra-Arterial Allogeneic Mesenchymal Stem Cells for Critical Limb

- Ischemia Are Safe and Efficacious: Report of a Phase I Study. *World J. Surg.* 37, 915–922. doi:10.1007/s00268-012-1892-6
- De Clercq, P. (2003). *Guideline-Based Decision Support in Medicine*. Citeseer.
- Dubsky, M., Jirkovska, A., Bem, R., Fejfarova, V., Pagacova, L., Sixta, B., et al. (2013). Both Autologous Bone Marrow Mononuclear Cell and Peripheral Blood Progenitor Cell Therapies Similarly Improve Ischaemia in Patients with Diabetic Foot in Comparison with Control Treatment. *Diabetes/Metabolism Res. Rev.* 29, 369–376. doi:10.1002/dmrr.2399
- Ebrahimi-Barough, S., Hoveizi, E., Norouzi Javidan, A., and Ai, J. (2015). Investigating the Neuroglial Differentiation Effect of Neuroblastoma Conditioned Medium in Human Endometrial Stem Cells Cultured on 3D Nanofibrous Scaffold. *J. Biomed. Mater. Res. A* 103, 2621–2627. doi:10.1002/jbm.a.35397
- Ebrahimi-Barough, S., Kouchesfahani, H. M., Ai, J., and Massumi, M. (2013a). Differentiation of Human Endometrial Stromal Cells into Oligodendrocyte Progenitor Cells (OPCs). *J. Mol. Neurosci.* 51, 265–273. doi:10.1007/s12031-013-9957-z
- Ebrahimi-Barough, S., Massumi, M., Kouchesfahani, H. M., and Ai, J. (2013b). Derivation of Pre-Oligodendrocytes from Human Endometrial Stromal Cells by Using Overexpression of microRNA 338. *J. Mol. Neurosci.* 51, 337–343. doi:10.1007/s12031-013-0101-x
- Emadedin, M., Aghdami, N., Taghiyar, L., Fazeli, R., Moghadasali, R., Jahangir, S., et al. (2012). Intra-Articular Injection of Autologous Mesenchymal Stem Cells in Six Patients with Knee Osteoarthritis. *Arch. Iranian Med.* 15, 422.
- Emadedin, M., Labibzadeh, N., Liastani, M. G., Karimi, A., Jaroughi, N., Bolurieh, T., et al. (2018). Intra-Articular Implantation of Autologous Bone Marrow-Derived Mesenchymal Stromal Cells to Treat Knee Osteoarthritis: a Randomized, Triple-Blind, Placebo-Controlled Phase 1/2 Clinical Trial. *Cytotherapy* 20, 1238–1246. doi:10.1016/j.jcyt.2018.08.005
- Emea, E. (2008). *Guideline on Human Cell-Based Medicinal Products*. Great Britain: Official Guideline of the European Medicines Agency: EMA London.
- Esfandiari, N., Ai, J., Nazemian, Z., Javed, M. H., Gotlieb, L., and Casper, R. F. (2007a). Expression of Glycodelin and Cyclooxygenase-2 in Human Endometrial Tissue Following Three-Dimensional Culture. *Am. J. Reprod. Immunol.* 57, 49–54. doi:10.1111/j.1600-0897.2006.00445.x
- Esfandiari, N., Khazaei, M., Ai, J., Bielecki, R., Gotlieb, L., Ryan, E., et al. (2007b). Effect of a Statin on an *In Vitro* Model of Endometriosis. *Fertil. Sterility* 87, 257–262. doi:10.1016/j.fertnstert.2006.06.040
- Esfandiari, N., Khazaei, M., Ai, J., Nazemian, Z., Jolly, A., Casper, R. F., et al. (2008). Angiogenesis Following Three-Dimensional Culture of Isolated Human Endometrial Stromal Cells Revascularization and Endothelial Progenitor Cells in Stroke. *Am. J. Physiology-Cell Physiol.* 315, C664–C674.
- Esquiva, G., Grayston, A., and Rosell, A. (2018). Revascularization and Endothelial Progenitor Cells in Stroke. *Am. J. Physiology-Cell Physiol.* 315, C664–C674. doi:10.1152/ajpcell.00200.2018
- Evans, J., Salamonsen, L. A., Winship, A., and Menkhorst, E. (2016). PFertile Ground: Human Endometrial Programming and Lessons in Health and Disease. *Nat. Rev. Endocrinol.* 12, 654–667. doi:10.1038/nrendo.2016.116
- Faghihi, F., Jalali, H., Parivar, K., Kajbafzadeh, A., Roozafzoon, R., and Somayeh, E.-B. (2014). Evaluation of Differentiation Potential of Endometrial-Versus Bone Marrow Driven Mesenchymal Stem Cells into Myoblast-Like Cells. *IJCRLS* 4, 3992–3997.
- Fowkes, F., Aboyans, V., Fowkes, F., McDermott, M., and Sampson, U. (2017). Peripheral Artery Disease: Epidemiology and Global Perspectives. *Nat. Rev. Cardiol.* 14, 156–170. doi:10.1038/nrcardio.2016.179
- Friedrich, E. B., Walenta, K., Scharlau, J., Nickenig, G., and Werner, N. (2006). CD34-/CD133+/VEGFR-2+ Endothelial Progenitor Cell Subpopulation with Potent Vasoregenerative Capacities. *Circ. Res.* 98, e20–e25. doi:10.1161/01.RES.0000205765.28940.93
- Fuentealba, L. C., Obernier, K., and Alvarez-Buylla, A. (2012). Adult Neural Stem Cells Bridge Their Niche. *Cell Stem Cell* 10, 698–708. doi:10.1016/j.stem.2012.05.012
- Gang, E. J., Jeong, J. A., Hong, S. H., Hwang, S. H., Kim, S. W., Yang, I. H., et al. (2004). Skeletal Myogenic Differentiation of Mesenchymal Stem Cells Isolated from Human Umbilical Cord Blood. *Stem Cells* 22, 617–624. doi:10.1634/stemcells.22-4-617
- Gao, W., Chen, D., Liu, G., and Ran, X. (2019). Autologous Stem Cell Therapy for Peripheral Arterial Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Stem Cel. Res. Ther.* 10, 1–14. doi:10.1186/s13287-019-1254-5
- Gargett, C. E., Schwab, K. E., Zillwood, R. M., Nguyen, H. P., and Wu, D. (2009). Isolation and Culture of Epithelial Progenitors and Mesenchymal Stem Cells from Human Endometrium. *Biol. Reprod.* 80, 1136–1145. doi:10.1095/biolreprod.108.075226
- Ghazizadeh, Z., Fattahi, F., Mirzaei, M., Bayersaikhani, D., Lee, J., Chae, S., et al. (2018). Prospective Isolation of ISL1+ Cardiac Progenitors from Human ESCs for Myocardial Infarction Therapy. *Stem Cel. Rep.* 10, 848–859. doi:10.1016/j.stemcr.2018.01.037
- Giudice, L. C. (1994). Growth Factors and Growth Modulators in Human Uterine Endometrium: Their Potential Relevance to Reproductive Medicine. *Fertil. Sterility* 61, 1–17. doi:10.1016/s0015-0282(16)56447-4
- Gong, M., Yu, B., Wang, J., Wang, Y., Liu, M., Paul, C., et al. (2017). Mesenchymal Stem Cells Release Exosomes that Transfer miRNAs to Endothelial Cells and Promote Angiogenesis. *Oncotarget* 8, 45200. doi:10.18632/oncotarget.16778
- Goodarzi, A., Khanmohammadi, M., Ai, A., Khodayari, H., Ai, A., Farahani, M. S., et al. (2020). Simultaneous Impact of Atorvastatin and Mesenchymal Stem Cells for Glioblastoma Multiform Suppression in Rat Glioblastoma Multiform Model. *Mol. Biol. Rep.* 47, 7783–7795. doi:10.1007/s11033-020-05855-z
- Gupta, P. K., Chullikana, A., Parakh, R., Desai, S., Das, A., Gottipamula, S., et al. (2013). A Double Blind Randomized Placebo Controlled Phase I/II Study Assessing the Safety and Efficacy of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Critical Limb Ischemia. *J. Translational Med.* 11, 1–11. doi:10.1186/1479-5876-11-143
- Gupta, P. K., Krishna, M., Chullikana, A., Desai, S., Murugesan, R., Dutta, S., et al. (2017). Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy. *Stem Cell Translational Med.* 6, 689–699. doi:10.5966/sctm.2016-0237
- Halme, D. G., and Kessler, D. A. (2006). FDA Regulation of Stem-Cell-Based Therapies. *New Engl. J. Med.* 355, 1730. doi:10.1056/nejmhpr063086
- Harbom, L. J., Michel, N., and McConnell, M. J. (2018). Single-Cell Analysis of Diversity in Human Stem Cell-Derived Neurons. *Cel. Tissue Res.* 371, 171–179. doi:10.1007/s00441-017-2728-3
- Hasanzadeh, E., Ebrahimi-Barough, S., Mahmoodi, N., Mellati, A., Nekounam, H., Basiri, A., et al. (2021). Defining the Role of 17 β -Estradiol in Human Endometrial Stem Cells Differentiation into Neuron-Like Cells. *Cel. Biol. Int.* 45, 140–153. doi:10.1002/cbin.11478
- Hashemian, S.-M. R., Aliannejad, R., Zarrabi, M., Soleimani, M., Vosough, M., Hosseini, S.-E., et al. (2021). Mesenchymal Stem Cells Derived from Perinatal Tissues for Treatment of Critically Ill COVID-19-Induced ARDS Patients: A Case Series. *Stem Cel. Res. Ther.* 12, 1–12. doi:10.1186/s13287-021-02165-4
- Heath, H., Kudo, H., Renney, G., Ward, M., Cutillas, P., Goldin, R., et al. (2018). *The Pathogenic Role of Stat2 in Inflammation Is Independent of Canonical Interferon Signaling and Is Mediated by TNFa*.
- Heldman, A. W., Difede, D. L., Fishman, J. E., Zambrano, J. P., Trachtenberg, B. H., Karantalis, V., et al. (2014). Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy: The TAC-HFT Randomized Trial. *Jama* 311, 62–73. doi:10.1001/jama.2013.282909
- Heo, W., Jun, H. J., Do Kyun Kang, H.-K. M., Hwang, Y.-H., Kim, J. Y., and Nam, K. H. (2017). Acute Limb Ischemia and Coronary Artery Disease in a Case of Kimura's Disease. *Korean J. Thorac. Cardiovasc. Surg.* 50, 114. doi:10.5090/kjtc.2017.50.2.114
- Hicks, C. W., and Selvin, E. (2019). Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Curr. Diabetes Rep.* 19, 1–8. doi:10.1007/s11892-019-1212-8
- Hong, S. H., Gang, E. J., Jeong, J. A., Ahn, C., Hwang, S. H., Yang, I. H., et al. (2005). *In Vitro* Differentiation of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells into Hepatocyte-Like Cells. *Biochem. Biophysical Res. Commun.* 330, 1153–1161. doi:10.1016/j.bbrc.2005.03.086
- Howangyin, K.-Y., Loinard, C., Bakker, W., Guérin, C. L., Vilar, J., D'audigier, C., et al. (2014). HIF-Prolyl Hydroxylase 2 Inhibition Enhances the Efficiency of Mesenchymal Stem Cell-Based Therapies for the Treatment of Critical Limb Ischemia. *Stem Cells* 32, 231–243. doi:10.1002/stem.1540
- Huang, W. J., Chen, W. W., and Zhang, X. (2016). Glioblastoma Multiforme: Effect of Hypoxia and Hypoxia Inducible Factors on Therapeutic Approaches. *Oncol. Lett.* 12, 2283–2288. doi:10.3892/ol.2016.4952

- Indo, H. P., Davidson, M., Yen, H.-C., Suenaga, S., Tomita, K., Nishii, T., et al. (2007). Evidence of ROS Generation by Mitochondria in Cells with Impaired Electron Transport Chain and Mitochondrial DNA Damage. *Mitochondrion* 7, 106–118. doi:10.1016/j.mito.2006.11.026
- Jaluvka, F., Ihnat, P., Madaric, J., Vrtkova, A., Janosek, J., and Prochazka, V. (2020). Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia. *Int. J. Mol. Sci.* 21, 8999. doi:10.3390/ijms21238999
- Jo, H.-Y., Han, H.-W., Jung, I., Ju, J. H., Park, S.-J., Moon, S., et al. (2020). Development of Genetic Quality Tests for Good Manufacturing Practice-Compliant Induced Pluripotent Stem Cells and Their Derivatives. *Scientific Rep.* 10, 1–15. doi:10.1038/s41598-020-60466-9
- Johnson, G. L., Henry, T. D., Povsic, T. J., Losordo, D. W., Garberich, R. F., Stanberry, L. I., et al. (2020). CD34+ Cell Therapy Significantly Reduces Adverse Cardiac Events, Health Care Expenditures, and Mortality in Patients with Refractory Angina. *Stem Cell Translational Med.* 9, 1147–1152. doi:10.1002/sctm.20-0046
- Johnson, T., Zhao, L., Manuel, G., Taylor, H., and Liu, D. (2019). Approaches to Therapeutic Angiogenesis for Ischemic Heart Disease. *J. Mol. Med.* 97, 141–151. doi:10.1007/s00109-018-1729-3
- Kalladka, D., Sinden, J., Pollock, K., Haig, C., Mclean, J., Smith, W., et al. (2016). Human Neural Stem Cells in Patients with Chronic Ischaemic Stroke (PISCES): a Phase 1, First-In-Man Study. *The Lancet* 388, 787–796. doi:10.1016/s0140-6736(16)30513-x
- Kamezaki, K., Shimoda, K., Numata, A., Haro, T., Kakumitsu, H., Yoshie, M., et al. (2005). Roles of Stat3 and ERK in G-CSF Signaling. *Stem Cells* 23, 252–263. doi:10.1634/stemcells.2004-0173a
- Kaneko, N., Kako, E., and Sawamoto, K. (2011). Prospects and Limitations of Using Endogenous Neural Stem Cells for Brain Regeneration. *Genes* 2, 107–130. doi:10.3390/genes2010107
- Kawamoto, A., Katayama, M., Handa, N., Kinoshita, M., Takano, H., Horii, M., et al. (2009). Intramuscular Transplantation of G-CSF-Mobilized CD34+ Cells in Patients with Critical Limb Ischemia: A Phase I/IIa, Multicenter, Single-Blinded, Dose-Escalation Clinical Trial. *Stem Cells* 27, 2857–2864. doi:10.1002/stem.207
- Keating, A. (2012). Mesenchymal Stromal Cells: New Directions. *Cell Stem Cell* 10, 709–716. doi:10.1016/j.stem.2012.05.015
- Khademi, F., Verdi, J., Soleimani, M., Roozafzoon, R., Keshel, S. H., Raeisossadati, R., et al. (2014). Human Endometrial Adult Stem Cells Can Be Differentiated into Hepatocyte Cells. *J. Med. Hypotheses Ideas* 8, 30–33. doi:10.1016/j.jmhi.2013.07.004
- Khalighfar, S., Khori, V., Alizadeh, A. M., Vahabzadeh, G., Tajaldini, M., Sedighi, S., et al. (2021). Dual Effects of Atorvastatin on Angiogenesis Pathways in the Differentiation of Mesenchymal Stem Cells. *Eur. J. Pharmacol.* 174281. doi:10.1016/j.ejphar.2021.174281
- Khodayari, H., Khodayari, S., Ebrahimi, E., Hadjilooei, F., Vesovic, M., Mahmoodzadeh, H., et al. (2021a). Stem Cells-Derived Natural Killer Cells for Cancer Immunotherapy: Current Protocols, Feasibility, and Benefits of Ex Vivo Generated Natural Killer Cells in Treatment of Advanced Solid Tumors. *Cancer Immunol. Immunother.* 70, 3369–3395. doi:10.1007/s00262-021-02975-8
- Khodayari, H., Khodayari, S., Khalighfar, S., Tahmasebifar, A., Tajaldini, M., Poorkhani, A., et al. (2021b). Gamma-Radiated Immunosuppressed Tumor Xenograft Mice Can Be a New Ideal Model in Cancer Research. *Scientific Rep.* 11, 1–13. doi:10.1038/s41598-020-80428-5
- Khodayari, S., Khodayari, H., Amiri, A. Z., Eslami, M., Farhud, D., Hescheler, J., et al. (2019). Inflammatory Microenvironment of Acute Myocardial Infarction Prevents Regeneration of Heart with Stem Cells Therapy. *Cell Physiol. Biochem.* 53, 887–909. doi:10.33594/000000180
- Kim, J.-Y., Morgan, M., Kim, D.-G., Lee, J.-Y., Bai, L., Lin, Y., et al. (2011). Tnf-Induced Noncanonical NF- κ B Activation Is Attenuated by RIP1 Through Stabilization of TRAF2. *J. Cell. Sci.* 124, 647–656. doi:10.1242/jcs.075770
- Kim, J., Kim, B., Kim, S., Lee, Y. I., Kim, J., and Lee, J. H. (2020). The Effect of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Media Containing Serum on Recovery After Laser Treatment: A Double-Blinded, Randomized, Split-Face Controlled Study. *J. Cosmet. Dermatol.* 19, 651–656. doi:10.1111/jocd.13063
- Kim, S. H., Cho, J. H., Lee, Y. H., Lee, J. H., Kim, S. S., Kim, M. Y., et al. (2018). Improvement in Left Ventricular Function with Intracoronary Mesenchymal Stem Cell Therapy in a Patient with Anterior Wall ST-Segment Elevation Myocardial Infarction. *Cardiovasc. Drugs Ther.* 32, 329–338. doi:10.1007/s10557-018-6804-z
- Kinnaird, T., Stabile, E., Burnett, M., Shou, M., Lee, C., Barr, S., et al. (2004). Local Delivery of Marrow-Derived Stromal Cells Augments Collateral Perfusion Through Paracrine Mechanisms. *Circulation* 109, 1543–1549. doi:10.1161/01.cir.0000124062.31102.57
- Kinoshita, M., Fujita, Y., Katayama, M., Baba, R., Shibakawa, M., Yoshikawa, K., et al. (2012). Long-Term Clinical Outcome after Intramuscular Transplantation of Granulocyte colony Stimulating Factor-Mobilized CD34 Positive Cells in Patients with Critical Limb Ischemia. *Atherosclerosis* 224, 440–445. doi:10.1016/j.atherosclerosis.2012.07.031
- Krenning, G., Strate, B. V. D., Schipper, M., Van Seijen, X. G. Y., Fernandes, B. C., Van Luyn, M. J., et al. (2009). CD34+ Cells Augment Endothelial Cell Differentiation of CD14+ Endothelial Progenitor Cells In Vitro. *J. Cell. Mol. Med.* 13, 2521–2533. doi:10.1111/j.1582-4934.2008.00479.x
- Kudo, F., Nishibe, T., Nishibe, M., and Yasuda, K. (2003). Autologous Transplantation of Peripheral Blood Endothelial Progenitor Cells (CD34 Sup+) for Therapeutic Angiogenesis in Patients with Critical Limb Ischemia. *Int. angiology* 22, 344.
- Lambert, M., and Belch, J. (2013). Medical Management of Critical Limb Ischaemia: Where Do We Stand Today? *J. Intern. Med.* 274, 295–307. doi:10.1111/joim.12102
- Laurence, J., Baptista, P., and Atala, A. (2015). *Translating Regenerative Medicine to the Clinic*. Academic Press.
- Lee, F.-Y., Chen, Y.-L., Sung, P.-H., Ma, M.-C., Pei, S.-N., Wu, C.-J., et al. (2015). Intracoronary Transfusion of Circulation-Derived CD34+ Cells Improves Left Ventricular Function in Patients with End-Stage Diffuse Coronary Artery Disease Unsuitable for Coronary Intervention. *Read. Online Crit. Care Med. So.y Crit. Care Me.e* 43, 2117–2132. doi:10.1097/ccm.0000000000001138
- Lee, H. B., Yu, M. R., Song, J. S., and Ha, H. (2004). Reactive Oxygen Species Amplify Protein Kinase C Signaling in High Glucose-Induced Fibronectin Expression by Human Peritoneal Mesothelial Cells. *Kidney Int.* 65, 1170–1179. doi:10.1111/j.1523-1755.2004.00491.x
- Leslie, N. R., Lindsay, Y., Ross, S. H., and Downes, C. P. (2004). Redox Regulation of Phosphatase Function. *Biochem. Soc. Trans.* 32, 1018–1020. doi:10.1042/BST0321018
- Levy, M. L., Crawford, J. R., Dib, N., Verkh, L., Tankovich, N., and Cramer, S. C. (2019). Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. *Stroke* 50, 2835–2841. doi:10.1161/strokeaha.119.026318
- Li, S., Zhou, B., and Han, Z. C. (2006). Therapeutic Neovascularization by Transplantation of Mobilized Peripheral Blood Mononuclear Cells for Limb Ischemia. *Thromb. Haemost.* 95, 301–311. doi:10.1160/th05-06-0442
- Liang, J., Zhang, H., Kong, W., Deng, W., Wang, D., Feng, X., et al. (2018). Safety Analysis in Patients with Autoimmune Disease Receiving Allogeneic Mesenchymal Stem Cells Infusion: A Long-Term Retrospective Study. *Stem Cell Res. Ther.* 9, 1–10. doi:10.1186/s13287-018-1053-4
- Liang, T. W., Jester, A., Motaganahalli, R. L., Wilson, M. G., G'sell, P., Akingba, G. A., et al. (2016a). Autologous Bone Marrow Mononuclear Cell Therapy for Critical Limb Ischemia Is Effective and Durable. *J. Vasc. Surg.* 63, 1541–1545. doi:10.1016/j.jvs.2016.01.022
- Liang, X., Zhang, L., Wang, S., Han, Q., and Zhao, R. C. (2016b). Exosomes Secreted by Mesenchymal Stem Cells Promote Endothelial Cell Angiogenesis by Transferring miR-125a. *J. Cell. Sci.* 129, 2182–2189. doi:10.1242/jcs.170373
- Liotta, F., Annunziato, F., Castellani, S., Boddi, M., Alterini, B., Castellini, G., et al. (2018). Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients with Critical Limb Ischemia—the SCELTA Trial. *Circ. J.* 82, 1688–1698. doi:10.1253/circj.17-0720
- Liu, X., Fu, X., Dai, G., Wang, X., Zhang, Z., Cheng, H., et al. (2017). Comparative Analysis of Curative Effect of Bone Marrow Mesenchymal Stem Cell and Bone Marrow Mononuclear Cell Transplantation for Spastic Cerebral Palsy. *J. Translational Med.* 15, 1–9. doi:10.1186/s12967-017-1149-0
- Lobo, F., Kessinger, A., Landmark, J., Smith, D., Weisenburger, D., Wigton, R., et al. (1991). Addition of Peripheral Blood Stem Cells Collected without Mobilization Techniques to Transplanted Autologous Bone Marrow Did Not Hasten

- Marrow Recovery Following Myeloablative Therapy. *Bone Marrow Transplant.* 8, 389–392.
- Lu, D., Jiang, Y., Deng, W., Zhang, Y., Liang, Z., Wu, Q., et al. (2019). Long-Term Outcomes of BMMSC Compared with BMNC for Treatment of Critical Limb Ischemia and Foot Ulcer in Patients with Diabetes. *Cel. Transplant.* 28, 645–652. doi:10.1177/0963689719835177
- Mafi, P., Hindocha, S., Mafi, R., Griffin, M., and Khan, W. (2011). Suppl 2: Adult Mesenchymal Stem Cells and Cell Surface Characterization-A Systematic Review of the Literature. *Open Orthopaedics J.* 5, 253. doi:10.2174/1874325001105010253
- Makhlough, A., Shekarchian, S., Moghadasali, R., Einollahi, B., Dastgheib, M., Janbabaee, G., et al. (2018). Bone Marrow–Mesenchymal Stromal Cell Infusion in Patients with Chronic Kidney Disease: A Safety Study with 18 Months of Follow-Up. *Cytotherapy* 20, 660–669. doi:10.1016/j.jcyt.2018.02.368
- Makhlough, A., Shekarchian, S., Moghadasali, R., Einollahi, B., Hosseini, S. E., Jaroughi, N., et al. (2017). Safety and Tolerability of Autologous Bone Marrow Mesenchymal Stromal Cells in ADPKD Patients. *Stem Cell Res. Ther.* 8, 1–11. doi:10.1186/s13287-017-0557-7
- Mardanpour, P., Nayernia, K., Khodayari, S., Khodayari, H., Molcanyi, M., and Hescheler, J. (2019). Application of Stem Cell Technologies to Regenerate Injured Myocardium and Improve Cardiac Function. *Cel. Physiol. Biochem.* 53, 101–120. doi:10.33594/000000124
- Matsiko, A., Levingstone, T. J., and O'Brien, F. J. (2013). Advanced Strategies for Articular Cartilage Defect Repair. *Materials* 6, 637–668. doi:10.3390/ma6020637
- Meng, X., Ichim, T. E., Zhong, J., Rogers, A., Yin, Z., Jackson, J., et al. (2007). Endometrial Regenerative Cells: A Novel Stem Cell Population. *J. Translational Med.* 5, 1–10. doi:10.1186/1479-5876-5-57
- Mirzaei, E., Ai, J., Ebrahimi-Barough, S., Verdi, J., Ghanbari, H., and Faridi-Majidi, R. (2016). The Differentiation of Human Endometrial Stem Cells into Neuron-Like Cells on Electrospun PAN-Derived Carbon Nanofibers with Random and Aligned Topographies. *Mol. Neurobiol.* 53, 4798–4808. doi:10.1007/s12035-015-9410-0
- Mobarakeh, Z. T., Ai, J., Yazdani, F., Sorkhabadi, S. M. R., Ghanbari, Z., Javidan, A. N., et al. (2012). Human Endometrial Stem Cells as a New Source for Programming to Neural Cells. *Cel. Biol. Int. Rep.* 19, 7–14. doi:10.1042/cbr20110009
- Mohamadi, F., Ebrahimi-Barough, S., Nourani, M. R., Mansoori, K., Salehi, M., Alizadeh, A. A., et al. (2018). Enhanced Sciatic Nerve Regeneration by Human Endometrial Stem Cells in an Electrospun Poly (ϵ -Caprolactone)/Collagen/NBG Nerve Conduit in Rat. *Artif. Cell Nanomedicine, Biotechnol.* 46, 1731–1743. doi:10.1080/21691401.2017.1391823
- Mohamadnejad, M., Vosough, M., Moossavi, S., Nikfam, S., Mardpour, S., Akhlaghpour, S., et al. (2016). Intraportal Infusion of Bone Marrow Mononuclear or CD133+ Cells in Patients with Decompensated Cirrhosis: a Double-blind Randomized Controlled Trial. *Stem Cell translational Med.* 5, 87–94. doi:10.5966/sctm.2015-0004
- Mohamed, S. A., Howard, L., Mcinerney, V., Hayat, A., Krawczyk, J., Naughton, S., et al. (2020). Autologous Bone Marrow Mesenchymal Stromal Cell Therapy for “No-option” Critical Limb Ischemia Is Limited by Karyotype Abnormalities. *Cytotherapy* 22, 313–321. doi:10.1016/j.jcyt.2020.02.007
- Molavi, B., Zafarghandi, M., Aminizadeh, E., Hosseini, S. E., Mirzayi, H., Arab, L., et al. (2016). Safety and Efficacy of Repeated Bone Marrow Mononuclear Cell Therapy in Patients with Critical Limb Ischemia in a Pilot Randomized Controlled Trial. *Arch. Iranian Med.* 19, 388–396.
- Moniche, F., Escudero, I., Zapata-Arriaza, E., Usero-Ruiz, M., Prieto-León, M., De La Torre, J., et al. (2015). Intra-arterial Bone Marrow Mononuclear Cells (BM-MNCs) Transplantation in Acute Ischemic Stroke (IBIS Trial): Protocol of a Phase II, Randomized, Dose-Finding, Controlled Multicenter Trial. *Int. J. Stroke* 10, 1149–1152. doi:10.1111/ijss.12520
- Muir, K. W., Bulters, D., Willmot, M., Sprigg, N., Dixit, A., Ward, N., et al. (2020). Intracerebral Implantation of Human Neural Stem Cells and Motor Recovery after Stroke: Multicentre Prospective Single-Arm Study (PISCES-2). *J. Neurol. Neurosurg. Psychiatry* 91, 396–401. doi:10.1136/jnnp-2019-322515
- Murphy, M. P., Wang, H., Patel, A. N., Kambhampati, S., Angle, N., Chan, K., et al. (2008). Allogeneic Endometrial Regenerative Cells: an “off the Shelf Solution” for Critical Limb Ischemia? *J. translational Med.* 6, 1–8. doi:10.1186/1479-5876-6-45
- Mutirangura, P., Ruangsetakit, C., Wongwanit, C., Chinsakchai, K., Porat, Y., Belleli, A., et al. (2009). Enhancing Limb Salvage by Non-Mobilized Peripheral Blood Angiogenic Cell Precursors Therapy in Patients with Critical Limb Ischemia. *J. Med. Assoc. Thai* 92, 320–327.
- Narula, N., Dannenberg, A. J., Olin, J. W., Bhatt, D. L., Johnson, K. W., Nadkarni, G., et al. (2018). Pathology of Peripheral Artery Disease in Patients with Critical Limb Ischemia. *J. Am. Coll. Cardiol.* 72, 2152–2163. doi:10.1016/j.jacc.2018.08.002
- Navaei-Nigjeh, M., Amoabedini, G., Noroozi, A., Azami, M., Asmani, M. N., Ebrahimi-Barough, S., et al. (2014). Enhancing Neuronal Growth from Human Endometrial Stem Cells Derived Neuron-Like Cells in Three-Dimensional Fibrin Gel for Nerve Tissue Engineering. *J. Biomed. Mater. Res. Part A* 102, 2533–2543. doi:10.1002/jbm.a.34921
- Ohtake, T., Mochida, Y., Ishioka, K., Oka, M., Maesato, K., Moriya, H., et al. (2018). Autologous Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood CD34 Positive Cell Transplantation for Hemodialysis Patients with Critical Limb Ischemia: A Prospective Phase II Clinical Trial. *Stem Cell Translational Med.* 7, 774–782. doi:10.1002/sctm.18-0104
- Pan, T., Liu, H., Fang, Y., Wei, Z., Gu, S., Fang, G., et al. (2019). Predictors of Responders to Mononuclear Stem Cell-Based Therapeutic Angiogenesis for No-Option Critical Limb Ischemia. *Stem Cell Res. Ther.* 10, 1–13. doi:10.1186/s13287-018-1117-5
- Park, C.-H., Bae, S. H., Kim, H. Y., Kim, J. K., Jung, E. S., Chun, H. J., et al. (2013). A Pilot Study of Autologous CD34-Depleted Bone Marrow Mononuclear Cell Transplantation via the Hepatic Artery in Five Patients with Liver Failure. *Cytotherapy* 15, 1571–1579. doi:10.1016/j.jcyt.2013.05.013
- Peplow, P. V. (2014). Growth Factor-And Cytokine-Stimulated Endothelial Progenitor Cells in Post-Ischemic Cerebral Neovascularization. *Neural Regen. Res.* 9, 1425. doi:10.4103/1673-5374.139457
- Perrelli, M.-G., Pagliaro, P., and Penna, C. (2011). Ischemia/Reperfusion Injury and Cardioprotective Mechanisms: Role of Mitochondria and Reactive Oxygen Species. *World J. Cardiol.* 3, 186. doi:10.4330/wjc.v3.i6.186
- Phinney, D. G., and Pittenger, M. F. (2017). Concise Review: MSC-Derived Exosomes for Cell-free Therapy. *Stem Cells* 35, 851–858. doi:10.1002/stem.2575
- Piccinato, C. A., Sertie, A. L., Torres, N., Ferretti, M., and Antonoli, E. (2015). High OCT4 and Low Expressions Determine *In Vitro* Lifespan of Mesenchymal Stem Cells. *Stem Cell Int.* 2015. doi:10.1155/2015/369828
- Piccirillo, N., Ausoni, G., Chiusolo, P., Sorà, F., Putzulu, R., Bianchi, M., et al. (2013). Twenty Years of Unrestricted Hematopoietic Stem Cell Collection and Storage: Impact of Joint Accreditation Committee International Society for Cellular Therapy Europe Standards Implementation on Stem Cell Storage Policy and Resource Utilization. *Cytotherapy* 15, 519–521. doi:10.1016/j.jcyt.2012.12.003
- Pignon, B., Sevestre, M.-A., Kanagaratnam, L., Pernod, G., Stephan, D., Emmerich, J., et al. (2017). Autologous Bone Marrow Mononuclear Cell Implantation and its Impact on the Outcome of Patients with Critical Limb Ischemia—Results of a Randomized, Double-Blind, Placebo-Controlled Trial. *Circ. J.* 81, 1713–1720. doi:10.1253/circj.cj-17-0045
- Pluchino, S., Smith, J. A., and Peruzzotti-Jametti, L. (2020). Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis. *Trends Mol. Med.* 26, 898–912. doi:10.1016/j.molmed.2020.04.005
- Portnow, J., Synold, T. W., Badie, B., Tirughana, R., Lacey, S. F., D'apuzzo, M., et al. (2017). Neural Stem Cell-Based Anticancer Gene Therapy: A First-In-Human Study in Recurrent High-Grade Glioma Patients. *Clin. Cancer Res.* 23, 2951–2960. doi:10.1158/1078-0432.ccr-16-1518
- Prianishnikov, V. (1978). On the Concept of Stem Cell and a Model of Functional-Morphological Structure of the Endometrium. *Contraception* 18, 213–223. doi:10.1016/s0010-7824(78)80015-8
- Qiu, Z., Zhu, L., He, L., Chen, D., Zeng, D., Chen, G., et al. (2019). DNA Damage and Reactive Oxygen Species Cause Cell Death in the rice Local Lesions 1 Mutant Under High Light and High Temperature. *New Phytol.* 222, 349–365. doi:10.1111/nph.15597
- Reali, C., Scintu, F., Pillai, R., Cabras, S., Argioli, F., Ristaldi, M. S., et al. (2006). Differentiation of Human Adult CD34+ Stem Cells into Cells with a Neural Phenotype: Role of Astrocytes. *Exp. Neurol.* 197, 399–406. doi:10.1016/j.expneurol.2005.10.004
- Rigato, M., Monami, M., and Fadini, G. P. (2017). Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of

- Randomized, Nonrandomized, and Noncontrolled Studies. *Circ. Res.* 120, 1326–1340. doi:10.1161/circresaha.116.309045
- Rink, B. E., Amilon, K. R., Esteves, C. L., French, H. M., Watson, E., Aurich, C., et al. (2017). Isolation and Characterization of Equine Endometrial Mesenchymal Stromal Cells. *Stem Cell Res. Ther.* 8, 1–12. doi:10.1186/s13287-017-0616-0
- Sarasúa, J. G., López, S. P., Viejo, M. Á., Basterrechea, M. P., Rodríguez, A. F., Gutiérrez, A. F., et al. (2011). Treatment of Pressure Ulcers with Autologous Bone Marrow Nuclear Cells in Patients with Spinal Cord Injury. *J. Spinal Cord Med.* 34, 301–307. doi:10.1179/2045772311y.0000000010
- Sassoli, C., Nosi, D., Tani, A., Chellini, F., Mazzanti, B., Quercioli, F., et al. (2014). Defining the Role of Mesenchymal Stromal Cells on the Regulation of Matrix Metalloproteinases in Skeletal Muscle Cells. *Exp. Cell Res.* 323, 297–313. doi:10.1016/j.yexcr.2014.03.003
- Sasson, I. E., and Taylor, H. S. (2008). Stem Cells and the Pathogenesis of Endometriosis. *Ann. New York Acad. Sci.* 1127, 106–115. doi:10.1196/annals.1434.014
- Schröder, K., Zhang, M., Benkhoff, S., Mieth, A., Pliquett, R., Kosowski, J., et al. (2012). Nox4 Is a Protective Reactive Oxygen Species Generating Vascular NADPH Oxidase. *Circ. Res.* 110, 1217–1225. doi:10.1161/circresaha.112.267054
- Sedger, L. M., and McDermott, M. F. (2014). TNF and TNF-Receptors: From Mediators of Cell Death and Inflammation to Therapeutic Giants—Past, Present and Future. *Cytokine Growth Factor Rev.* 25, 453–472. doi:10.1016/j.cytogfr.2014.07.016
- Seebach, C., Henrich, D., Meier, S., Nau, C., Bonig, H., and Marzi, I. (2016). Safety and Feasibility of Cell-Based Therapy of Autologous Bone Marrow-Derived Mononuclear Cells in Plate-Stabilized Proximal Humeral Fractures in Humans. *J. Translational Med.* 14, 1–11. doi:10.1186/s12967-016-1066-7
- Seekamp, A., Warren, J. S., Remick, D., Till, G., and Ward, P. (1993). Requirements for Tumor Necrosis Factor-Alpha and Interleukin-1 in Limb Ischemia/Reperfusion Injury and Associated Lung Injury. *Am. J. Pathol.* 143, 453.
- Shamosi, A., Farokhi, M., Ai, J., and Sharifi, E. (2015). Induction of Spontaneous Neo-Angiogenesis and Tube Formation in Human Endometrial Stem Cells by Bioglass. *J. Med. Hypotheses Ideas* 9, 94–98. doi:10.1016/j.jmhi.2015.09.004
- Shamosi, A., Mehrabani, D., Azami, M., Ebrahimi-Barough, S., Siavashi, V., Ghanbari, H., et al. (2017). Differentiation of Human Endometrial Stem Cells into Endothelial-Like Cells on Gelatin/Chitosan/Bioglass Nanofibrous Scaffolds. *Artif. Cell Nanomedicine, Biotechnol.* 45, 163–173. doi:10.3109/21691401.2016.1138493
- Shi, M., Zhang, Z., Xu, R., Lin, H., Fu, J., Zou, Z., et al. (2012). Human Mesenchymal Stem Cell Transfusion Is Safe and Improves Liver Function in Acute-on-Chronic Liver Failure Patients. *Stem Cell Translational Med.* 1, 725–731. doi:10.5966/sctm.2012-0034
- Shirian, S., Ebrahimi-Barough, S., Saberi, H., Norouzi-Javidan, A., Mousavi, S. M. M., Derakhshan, M. A., et al. (2016). Comparison of Capability of Human Bone Marrow Mesenchymal Stem Cells and Endometrial Stem Cells to Differentiate into Motor Neurons on Electrospun Poly (ϵ -Caprolactone) Scaffold. *Mol. Neurobiol.* 53, 5278–5287. doi:10.1007/s12035-015-9442-5
- Shoji, K., Zen, K., Yanishi, K., Wakana, N., Nakanishi, N., Nakamura, T., et al. (2020). Two Effective Cases of Additional Pedal Artery Angioplasty for Severe Lower Limb Ischemia Following Acute Thrombotic Artery Occlusion with Hypercoagulable State Diseases. *CVIR Endovascular* 3, 1–5. doi:10.1186/s42155-020-00166-7
- Simon, F., Oberhuber, A., Floros, N., Busch, A., Wagenhäuser, M. U., Schelzig, H., et al. (2018). Acute Limb Ischemia—Much More Than Just a Lack of Oxygen. *Int. J. Mol. Sci.* 19, 374. doi:10.3390/ijms19020374
- Singer, W., Dietz, A. B., Zeller, A. D., Gehrking, T. L., Schmelzer, J. D., Schmeichel, A. M., et al. (2019). Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy. *Neurology* 93, e77–e87. doi:10.1212/wnl.00000000000007720
- Steiling, H., Munz, B., Werner, S., and Brauchle, M. (1999). Different Types of ROS-Scavenging Enzymes Are Expressed During Cutaneous Wound Repair. *Exp. Cell Res.* 247, 484–494. doi:10.1006/excr.1998.4366
- Stein, J., Steven, S., Bros, M., Sudowe, S., Hausding, M., Oelze, M., et al. (2017). Role of Protein Kinase C and Nox2-Derived Reactive Oxygen Species Formation in the Activation and Maturation of Dendritic Cells by Phorbol Ester and Lipopolysaccharide. *Oxidative Med. Cell. Longevity* 2017, 4157213. doi:10.1155/2017/4157213
- Sullivan, R., Dailey, T., Duncan, K., Abel, N., and Borlongan, C. V. (2016). Peripheral Nerve Injury: Stem Cell Therapy and Peripheral Nerve Transfer. *Int. J. Mol. Sci.* 17, 2101. doi:10.3390/ijms17122101
- Tabatabaei, F. S., Ai, J., Kashi, T. S. J., Khazaei, M., Kajbafzadeh, A.-M., and Ghanbari, Z. (2013). Effect of Dentine Matrix Proteins on Human Endometrial Adult Stem-Like Cells: *In Vitro* Regeneration of Odontoblasts Cells. *Arch. Oral Biol.* 58, 871–879. doi:10.1016/j.archoralbio.2013.01.013
- Taghdiri Nooshabadi, V., Verdi, J., Ebrahimi-Barough, S., Mowla, J., Atlasi, M. A., Mazoochi, T., et al. (2019). Endometrial Mesenchymal Stem Cell-Derived Exosome Promote Endothelial Cell Angiogenesis in a Dose Dependent Manner: A New Perspective on Regenerative Medicine and Cell-Free Therapy. *Arch. Neurosci.* 6. doi:10.5812/ans.94041
- Tanaka, R., Masuda, H., Kato, S., Imagawa, K., Kanabuchi, K., Nakashioya, C., et al. (2014). Autologous G-CSF-Mobilized Peripheral Blood CD34+ Cell Therapy for Diabetic Patients with Chronic Nonhealing Ulcer. *Cel. Transplant.* 23, 167–179. doi:10.3727/096368912x658007
- Tanniou, J., Van Der Tweel, I., Teerenstra, S., and Roes, K. C. (2016). Subgroup Analyses in Confirmatory Clinical Trials: Time to Be Specific About Their Purposes. *BMC Med. Res. Methodol.* 16, 1–15. doi:10.1186/s12874-016-0122-6
- Tao, H., Han, Z., Han, Z. C., and Li, Z. (2016). Proangiogenic Features of Mesenchymal Stem Cells and Their Therapeutic Applications. *Stem Cell Int.* 2016. doi:10.1155/2016/1314709
- Tateishi-Yuyama, E., Matsubara, H., Murohara, T., Ikeda, U., Shintani, S., Masaki, H., et al. (2002). Therapeutic Angiogenesis for Patients with Limb Ischaemia by Autologous Transplantation of Bone-Marrow Cells: A Pilot Study and a Randomised Controlled Trial. *The Lancet* 360, 427–435. doi:10.1016/s0140-6736(02)09670-8
- Tehrani, H. J., Parivar, K., Ai, J., Kajbafzadeh, A., Rahbarghazi, R., Hashemi, M., et al. (2014). Effect of Dexamethasone, Insulin and EGF on the Myogenic Potential on Human Endometrial Stem Cell. *Iranian J. Pharm. Res. IJPR* 13, 659.
- Tendera, M., Wojakowski, W., Rużyłło, W., Chojnowska, L., Kępka, C., Tracz, W., et al. (2009). Intracoronary Infusion of Bone Marrow-Derived Selected CD34+ CXCR4+ Cells and Non-Selected Mononuclear Cells in Patients with Acute STEMI and Reduced Left Ventricular Ejection Fraction: Results of Randomized, Multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. *Eur. Heart J.* 30, 1313–1321. doi:10.1093/eurheartj/ehp073
- Torbjörnsson, E., Fagerdahl, A.-M., Blomgren, L., Boström, L., Ottosson, C., and Malmstedt, J. (2021). Risk Factors for Reamputations in Patients Amputated after Revascularization for Critical Limb-Threatening Ischemia. *J. Vasc. Surg.* 73, 258–266. e251. doi:10.1016/j.jvs.2020.03.055
- Toyoda, M., Cui, C., and Umezawa, A. (2007). Myogenic Transdifferentiation of Menstrual Blood-Derived Cells. *Acta Myologica* 26, 176.
- Uccioli, L., Meloni, M., Izzo, V., Giurato, L., Merolla, S., and Gandini, R. (2018). Critical Limb Ischemia: Current Challenges and Future Prospects. *Vasc. Health Risk Manag.* 14, 63. doi:10.2147/vhrm.s125065
- Urbich, C., and Dimmeler, S. (2004). Endothelial Progenitor Cells: Characterization and Role in Vascular Biology. *Circ. Res.* 95, 343–353. doi:10.1161/01.res.0000137877.89448.78
- Verdi, J., Tan, A., Shoaie-Hassani, A., and Seifalian, A. M. (2014). Endometrial Stem Cells in Regenerative Medicine. *J. Biol. Eng.* 8, 1–10. doi:10.1186/1754-1611-8-20
- Viganò, M., Budelli, S., Lavazza, C., Montemurro, T., Montelatici, E., De Cesare, S., et al. (2018). Tips and Tricks for Validation of Quality Control Analytical Methods in Good Manufacturing Practice Mesenchymal Stromal Cell Production. *Stem Cell Int.* 2018. doi:10.1155/2018/3038565
- Wahid, F. S. A., Ismail, N. A., Wan Jamaludin, W. F., Muhamad, N. A., Mohamad Idris, M. A., and Lai, N. M. (2018). Efficacy and Safety of Autologous Cell-Based Therapy in Patients with No-Option Critical Limb Ischaemia: A Meta-Analysis. *Curr. Stem Cell Res. Ther.* 13, 265–283. doi:10.2174/1574888x13666180313141416
- Wang, Q., Guerrero, F., Mazur, A., Lambrechts, K., Buzzacott, P., Belhomme, M., et al. (2015). Reactive Oxygen Species, Mitochondria, and Endothelial Cell Death During *In Vitro* Simulated Dives. *Med. Sci. Sports Exerc.* 47, 1362–1371. doi:10.1249/mss.0000000000000563
- Wang, S. K., Green, L. A., Drucker, N. A., Motaganahalli, R. L., Fajardo, A., and Murphy, M. P. (2018). Rationale and Design of the Clinical and Histologic

- Analysis of Mesenchymal Stromal Cells in Amputations (CHAMP) Trial Investigating the Therapeutic Mechanism of Mesenchymal Stromal Cells in the Treatment of Critical Limb Ischemia. *J. Vasc. Surg.* 68, 176–181. e171. doi:10.1016/j.jvs.2017.09.057
- Weem, S. P., Teraa, M., Den Ruijter, H., De Borst, G., Verhaar, M., and Moll, F. (2016). Quality of Life After Treatment with Autologous Bone Marrow Derived Cells in No Option Severe Limb Ischemia. *Eur. J. Vasc. Endovascular Surg.* 51, 83–89. doi:10.1016/j.ejvs.2015.09.010
- Wijnand, J. G., Teraa, M., Gremmels, H., Van Rhijn-Brouwer, F. C., De Borst, G. J., Verhaar, M. C., et al. (2018). Rationale and Design of the SAIL Trial for Intramuscular Injection of Allogeneic Mesenchymal Stromal Cells in No-Option Critical Limb Ischemia. *J. Vasc. Surg.* 67, 656–661. doi:10.1016/j.jvs.2017.09.026
- Wilson, J. G., Liu, K. D., Zhuo, H., Caballero, L., Mcmillan, M., Fang, X., et al. (2015). Mesenchymal Stem (Stromal) Cells for Treatment of ARDS: A Phase 1 Clinical Trial. *Lancet Respir. Med.* 3, 24–32. doi:10.1016/s2213-2600(14)70291-7
- Wu, Z., Cai, J., Chen, J., Huang, L., Wu, W., Luo, F., et al. (2014). Autologous Bone Marrow Mononuclear Cell Infusion and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus: An Open-Label, Randomized Controlled Clinical Trial. *Cytotherapy* 16, 258–265. doi:10.1016/j.jcyt.2013.10.004
- Xia, C., Zeng, Z., Fang, B., Tao, M., Gu, C., Zheng, L., et al. (2019). Mesenchymal Stem Cell-Derived Exosomes Ameliorate Intervertebral Disc Degeneration via Anti-Oxidant and Anti-Inflammatory Effects. *Free Radic. Biol. Med.* 143, 1–15. doi:10.1016/j.freeradbiomed.2019.07.026
- Xiao, Z., Tang, F., Zhao, Y., Han, G., Yin, N., Li, X., et al. (2018). Significant Improvement of Acute Complete Spinal Cord Injury Patients Diagnosed by a Combined Criteria Implanted with Neuroregeneration Scaffolds and Mesenchymal Stem Cells. *Cel. Transplant.* 27, 907–915. doi:10.1177/0963689718766279
- Xu, B., Fan, D., Zhao, Y., Li, J., Wang, Z., Wang, J., et al. (2020). Three-Dimensional Culture Promotes the Differentiation of Human Dental Pulp Mesenchymal Stem Cells into Insulin-Producing Cells for Improving the Diabetes Therapy. *Front. Pharmacol.* 10, 1576. doi:10.3389/fphar.2019.01576
- Yamamoto, K., Kondo, T., Suzuki, S., Izawa, H., Kobayashi, M., Emi, N., et al. (2004). Molecular Evaluation of Endothelial Progenitor Cells in Patients with Ischemic Limbs: Therapeutic Effect by Stem Cell Transplantation. *Arteriosclerosis, Thromb. Vasc. Biol.* 24, E192–E196. doi:10.1161/01.ATV.0000147730.78953.60
- Yañez, R., Lamana, M. L., García-Castro, J., Colmenero, I., Ramirez, M., and Bueren, J. A. (2006). Adipose Tissue-Derived Mesenchymal Stem Cells Have *In Vivo* Immunosuppressive Properties Applicable for the Control of the Graft-Versus-Host Disease. *Stem Cells* 24, 2582–2591. doi:10.1634/stemcells.2006-0228
- Ye, J., and Yuan, L. (2007). Inhibition of P38 MAPK Reduces Tumor Conditioned Medium-Induced Angiogenesis in Co-cultured Human Umbilical Vein Endothelial Cells and Fibroblasts. *Biosci. Biotechnol. Biochem.* 71, 1162–1169. doi:10.1271/bbb.60617
- Yoon, Y., Kim, H. S., Jeon, I., Noh, J. E., Park, H. J., Lee, S., et al. (2020). Implantation of the Clinical-Grade Human Neural Stem Cell Line, CTX0E03, Rescues the Behavioral and Pathological Deficits in the Quinolinic Acid-Lesioned Rodent Model of Huntington's Disease. *Stem Cells* 38, 936–947. doi:10.1002/stem.3191
- Yu, J., and Dardik, A. (2018). A Murine Model of Hind Limb Ischemia to Study Angiogenesis and Arteriogenesis. *Traumatic Ischemic Inj.*, 135–143. doi:10.1007/978-1-4939-7526-6_11
- Zabel, M., Willems, R., Lubinski, A., Bauer, A., Brugada, J., Conen, D., et al. (2020). Clinical Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators: Results of the EU-CERT-ICD Controlled Multicentre Cohort Study. *Eur. Heart J.* 41, 3437–3447. doi:10.1093/eurheartj/ehaa226
- Zafarhandi, M. R., Ravari, H., Aghdami, N., Namiri, M., Moazzami, K., Taghiabadi, E., et al. (2010). Safety and Efficacy of Granulocyte-Colony-Stimulating Factor Administration Following Autologous Intramuscular Implantation of Bone Marrow Mononuclear Cells: A Randomized Controlled Trial in Patients with Advanced Lower Limb Ischemia. *Cytotherapy* 12, 783–791. doi:10.3109/14653240903518163
- Zannettino, A., Paton, S., Arthur, A., Khor, F., Itescu, S., Gimble, J., et al. (2008). Multipotential Human Adipose-Derived Stromal Stem Cells Exhibit a Perivascular Phenotype *In Vitro* and *In Vivo*. *J. Cell. Physiol.* 214, 413–421. doi:10.1002/jcp.21210
- Zhong, Z., Patel, A. N., Ichim, T. E., Riordan, N. H., Wang, H., Min, W.-P., et al. (2009). Feasibility Investigation of Allogeneic Endometrial Regenerative Cells. *J. Translational Med.* 7, 1–7. doi:10.1186/1479-5876-7-15
- Zhou, S.-B., Zhang, G.-Y., Xie, Y., Zan, T., Gan, Y.-K., Yao, C. A., et al. (2016). Autologous Stem Cell Transplantation Promotes Mechanical Stretch Induced Skin Regeneration: A Randomized Phase I/II Clinical Trial. *EBioMedicine* 13, 356–364. doi:10.1016/j.ebiom.2016.09.031
- Zhu, J., Song, J., Yu, L., Zheng, H., Zhou, B., Weng, S., et al. (2016). Safety and Efficacy of Autologous Thymosin β 4 Pre-Treated Endothelial Progenitor Cell Transplantation in Patients with Acute ST Segment Elevation Myocardial Infarction: A Pilot Study. *Cytotherapy* 18, 1037–1042. doi:10.1016/j.jcyt.2016.05.006

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Khodayari, Khodayari, Ebrahimi-Barough, Khanmohammadi, Islam, Vesovic, Goodarzi, Mahmoodzadeh, Nayernia, Aghdami and Ai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.